AUTHOR INDEX

Aaronson, S. A. 385, 402
Abacioglu, Y. H. 338, 347
Abouel-Makarem, M. M. 87, 96
Adachi, K. 201, 222
Adam-Vizi, V. 255, 264
Adams, P. D. 299, 303
Adenis, A. 143, 159
Admon, A. 123, 137
Adnane, J. 283, 301
Agranoff, B. W. 250, 260, 263–264
Aiba, A. 145–146, 160
Ajakane, M. 259, 264
Akerboom, T. P. M. 18–19, 28
Akerman, K. E. O. 246, 263
Aksoy, I. A. 386, 404
Aksoy, S. 386, 404
Al-Nasser, I. 187, 198
Alam, T. G. 10, 14
Alati, T. 367, 376, 380–381
Albers, M. W. 123, 137
Alberti, S. 365, 379
Alberts, A. S. 289, 302
Alexander, H. R. 144, 160
Alger, J. R. 260, 264
Alhadeff, J. A. 271, 280
Ali Imam, A. M. 165, 178
Allan, R. N. 375, 380
Allegra, C. J. 143–148, 150–153, 155, 159–162, 165, 171, 178–179
Allen, S. P. 187, 197
Alligood, K. 386, 403
Allison, A. C. 309, 323
Allison, J. H. 229, 243
Almersjo, O. 145, 160
Almquist, K. C. 17–19, 23, 27–28
Alteri, E. 386, 403
Amakawa, T. 130, 139
Ammer, H. 246, 263
Amy, C. 201, 222
Anderson, C. W. 155, 162
Anderson, R. A. 34, 54, 115–129, 132, 135–136, 138
Anderson, R. G. W. 365, 378
Andersson, S. 360, 363
Andis, S. L. 367, 369, 379
Andis, S. A. 368, 380
Andrake, M. 150, 161
Andreesen, R. 386, 404
Andress, D. L. 307, 323
Aneja, R. 115, 135
Aneja, S. 115, 135
Angelelli, B. 22, 29
Annels, S. J. 237, 243
Anraku, Y. 123–124, 126, 128, 137–138
Anthony, L. 19, 21–22, 28
Antoine, B. 208, 217, 223–224, 226
Antonsson, B. E. 260, 264
Aoyagi, T. 269, 276, 280–281
Appela, E. J. 155, 162
Appelhans, H. 333, 346
Arakawa, M. 320, 324
Araki, N. 322, 324
Arceci, R. J. 352, 362
Arfsten, A. E. 150, 161
Arian, W. J. 87, 96
Arias, I. M. 18, 26, 28–29, 351–352, 361–362
Armand, J. P. 386, 402
Armstrong, M. 201, 222
Arndt, C. 133, 139
Arnhold, M. 333, 346
Artemenko, I. P. 242, 244–246, 248–249, 253–254, 256, 263
Asano, M. 133, 140
Asfari, M. 207, 223
Ashendel, C. 386, 404
Ashford, V. A. 153, 162
Aspley, S. 246, 262
Atack, J. R. 246, 262
Atassi, H. 353, 362
Atsumi, S. 272–274, 276, 278, 281
Auger, K. R. 385, 402
Augustinas, O. 26, 29
Avril, L.-E. 338, 347
Avruch, J. 192, 198
Ayusawa, D. 145, 160, 165, 178
Azab, M. 143, 159
Azaroff, L. 94, 97
Azuma, M. 110, 113
Azzi, A. 387, 398, 404

Baas, F. 17–18, 22–23, 27, 352, 361
Babbitt, P. C. 168–169, 179
Bacchetti, S. 11, 14
Bachur, N. R. 22, 29
Bacon, P. E. 4–5, 10, 14
Bacote, V. 210, 224

Bagrij, T. 22, 29
Bailey, E. 201, 223
Baird, J. G. 246, 255, 263
Baker, H. 375, 380
Baker, R. M. 168, 179
Bakker, C. 94, 97
Baldassare, J. J. 397, 406
Baldwin, J. E. 34, 54
Ball, A. 129, 132, 138–139
Ballas, L. M. 115, 135
Balloy, V. 333, 346
Banay-Schwartz, M. 255, 264
Banfic, H. 105, 109–110, 113, 115–116, 133, 136
Bar-Tana, J. 19, 21, 28
Barker, P. J. 105, 113
Barnabei, O. 101, 110, 113
Barnaby, R. J. 246, 262
Barnwell, S. 357, 363
Barnwell, S. G. 357, 363
Barredo, J. 367, 379
Barrett, A. J. 309, 323
Bartel-Schwarze, S. 320, 323
Bartley, W. 201, 223
Bartrons, J. 205, 223
Bassing, C. H. 298, 303
Bastow, K. F. 153, 162
Basu, A. 386, 403
Battula, N. 353, 362
Batty, I. H. 241, 244
Baudet, V. 259, 264
Baudette, J. 4, 11–13
Baudon, M.-A. 202, 211, 223
Bavelloni, A. 101, 112
Bazenet, C. E. 34, 54, 115–117, 119–120, 122, 125, 136
Beardsley, G. P. 367, 379
Beaudette, N. 152, 161
Beck, J. 18, 22, 27
Beck, K.-F. 201, 222
Becker, F. F. 353, 362
Beermann, M. L. 246, 263
Beijnen, J. 17, 22, 27
Beijnen, J. H. 352, 362
Bell, C. C. 356, 363
Bellevergue, P. 259, 264
Bendovic, S. J. 152, 162, 367, 375, 379
Bennett, R. 19, 21–22, 28
Beppu, Y. 325
Berdel, W. E. 386–387, 404–405
Berg, P. 7, 14
Bergman, R. 212, 225
Bergot, M.-O. 214–215, 217, 225
Berkovic, D. 387, 405
Berlin, 123, 137
Bernardi, A. 150, 161
Berne, M. H. O. 145, 160
Berns, A. J. M. 352, 356, 362
Berra, E. 387, 405
Berridge, M. 58, 70
Berridge, M. J. 101, 112, 245–246, 255, 262, 387, 391, 405, 407
Bertagnolo, V. 101–102, 105, 107, 109–110, 112, 114, 133, 140
Berthon, B. 115, 136
Bertino, J. R. 165, 170, 178–179, 366, 379
Bessell, E. 211, 224
Beverley, P. C. L. 336, 346
Bewley, J. R. 369, 376, 380, 381
Beyer, R. 203, 223
Bhardwaj, G. 17, 18, 23, 27
Biedler, J. L. 246, 262
Biedler, J. L. J. 246, 262
Billi, A. M. 33–34, 54, 102–107, 109–110, 112–113
Bin Senafi, S. 86, 96
Birknes, B. 59, 65, 70
Biron, K. K. 9–10, 14
Bishop, J. M. 385, 402
Bittman, R. 387, 405
Black, A. R. 165
Blackman, F. F. 35, 55
Blair, J. A. 375, 380
Blakley, R. L. 152, 162, 367, 375, 379
Blanc, D. 325, 336, 345–346
Blanz, J. 22, 29
Blaskovich, M. A. 386, 403
Blazing, M. 298, 303
Boardman, L. A. 172, 180
Boarman, D. 145, 148, 161
Bock, K. W. 85, 87, 96
Bockaert, J. 240, 243
Boddy, A. 367, 380
Bode, W. 333, 345
Boe, R. 289, 302
Boersma, M. J. A. 338, 347
Bohme, M. 19, 21, 28
Boissin, P. 259, 264
Bokoch, G. M. 131, 139
Bollas, L. M. 87, 96
Bolognesi, D. P. 336, 338, 346
Bomalski, J. 59, 70
Bonmassar, E. 171, 179
Bonnard, C. 154, 162
Booker, G. W. 124, 138
Boonstra, J. 101, 110, 112, 115, 132–133, 136
Boquet, D. 214, 225
Borah, B. 68, 71
Borner, C. 386, 403
Boronenkov, I. V. 115, 122–128, 136, 138
Borst, P. 17–18, 20, 22–23, 27–28, 352–353, 356, 360–363
Bos, J. L. 133, 139

Bosc, D. 216–218, 225
Bosch, F. 209, 224
Boscoboinik, D. 387, 398, 404
Bosma, P. 94, 97
Bosze, P. 35, 55
Botti, G. 269, 280
Boursier, E. 259, 264
Boxer, M. 85, 86, 96
Boyer, J. L. 26, 29
Boyer, P. D. 183–184, 196
Brachwitz, H. 385–386, 404
Bradford, M. M. 77, 83
Bradley, A. 284, 301
Bradley, G. 355, 362
Brami, B. A. 257, 264
Branch, R. 19, 21–22, 28
Brann, M. R. 400, 406
Brauer, A. W. 124, 138
Bray, S. J. 4, 7, 10, 13
Braziani, A. 385, 402
Brener, L. 10, 14
Bresnick, E. 46, 55
Breton, M. 101, 110, 112, 115, 132–133, 136
Brewer, K. A. 115, 135
Brichard, S. 205–206, 223
Brierley, C. H. 85–86, 96
Brigle, K. E. 365, 379
Brini, M. 187–189, 198
Brockman, J. L. 34, 54, 115–117, 119–120, 122, 125, 136
Bron, R. F. 386, 404
Brooks, M. W. 279, 281
Brooksbank, C. E. L. 115, 119–120, 135
Bross, T. E. 250, 255, 263–264
Brown, D. 288, 302
Brown, E. J. 123, 137
Brown, M. 367, 379
Brown, N. C. 6–7, 14
Browning, K. S. 195, 198
Broxterman, H. J. 17–18, 22–23, 27, 29
Bruck, M. E. 133, 139
Bruhn, H. 260, 264
Brun, T. 207–208, 210–212, 220, 223
Brunton, V. G. 385–386, 402–403
Buchdunger, E. 386, 403
Buchholz, U. 17–22, 26–28
Buchler, M. 17–21, 23–28
Buchner, K. 105, 113, 387, 405
Buday, L. 279, 281
Burchell, B. 85–86, 88, 96
Burgess, G. M. 250, 257, 264
Burnett, P. 183, 188–189,198
Burns, D. J. 115, 135, 387, 405
Bursch, W. 288–289, 292, 297, 302
Burt, R. K. 353, 362
Busbee, D. 39, 41, 55, 133, 140
Buschman, E. 352, 362
Byberg, J. 59, 70
Byrn, R. A. 337, 346
Bystroff, C. 153, 162

Cacace, A. M. 387, 405
Cadman, E. 165, 178
Cai, R. Z. 386, 402
Calabrese, G. 110, 113
Calemard, E. 320, 323
Calvert, A. H. 367, 379–380
Camaggi, C. M. 22, 29
Cameron, V. 152, 161
Campbell, A. 60, 71
Campbell, I. D. 124, 138
Campbell, I. G. 365, 379
Canevari, S. 365, 379
Cano, J. P. 22, 29
Cantley, L. C. 115–116, 119, 123, 129–139
Capitani, S. 101, 110, 113–114
Capon, D. J. 337, 346
Caravatti, G. 386, 403
Carey, J. 152, 161
Carlson, R. O. 246, 263
Carney, W. P. 75, 83
Carozzi, A. 387, 400, 405
Carpenter, C. 385, 402
Carpenter, C. L. 115–116, 130–131, 135, 139
Carpenter, G. 116, 140
Carr, S. F. 76, 79, 82–83
Carreras, J. 205, 223
Carrier, F. 157, 163
Carriero, M. V. 269, 280
Carroza, M. 283, 301
Carter, G. L. 4, 14
Cartwright, C. A. 172, 179
Casey, J. L 146–147, 150, 161, 165, 178
Casey, T. T. 320, 323
Cashmore, A. R. 170, 179
Cataldi, A. 104, 113
Cataldo, A. 246, 263
Catapano, C. V. 76, 83
Cavender, A. 386, 403
Center, M. 19, 21, 28
Center, M. S. 17, 19, 23, 27
Cerra, M. 269, 280
Chabner, B. A. 146–147, 150, 161, 165, 171, 178–179
Chalifa, V. 116, 129, 138
Challis, R. A. J. 250, 255, 263
Challiss, J. R. A. 246, 262
Challiss, R. A. 246, 262
Challiss, R. A. J. 229, 240, 243, 246, 262
Chamaret, S. 336, 346

Chamberlain, J. P. 168, 179
Champagne, E. 336, 346
Chan, A. K. 10, 14
Chan, J. Y. 353, 362
Chang, C.-Y. 283–284, 301
Chang, K. J. 115, 131, 136
Chant, J. 130, 139
Chap, H. 115, 136
Chapkin, R. S. 387, 405
Charifson, P. 386, 403
Charon, D. 259, 264
Charra, B. 320, 323
Chassignol, M. 386, 403
Chaudhuri, P. K. 365–366, 371, 379
Chauvet, D. 208, 210, 213, 223
Che, M. 18, 28, 351, 361
Che, M. X. 352, 362
Chen, C. 68, 71
Chen, C.-S. 116, 129, 138
Chen, F. 86, 96
Chen, J. K. 124, 138
Chen, T. R. 171, 179
Cheng, Y. C. 153, 162
Cheng-Meyer, C. 342, 347
Chiang, J. Y. L. 360, 363
Chignard, M. 333, 346
Chin, J. E. 352, 362
Chin, J. G. 185, 197
Chirgwin, J. M. 168, 179
Chittenden, T. 287, 302
Chiu, M. I. 123, 137
Cho, Y. 386, 404
Choe, H. 68, 71
Choi, K. 352, 362,
Choi, K. D. 101, 112, 400, 407
Chomczynski, P. 355, 363
Chong, L. D. 131, 139
Choppin, P. W. 325, 328, 344
Chowdhury, J. Roy 94, 97
Chowdhury, J. R. 26, 29, 85, 96
Chowdhury, N. Roy 94, 97
Chowdhury, N. R. 26, 29
Choy, B. K. 10, 14
Chrivia, J. 218, 226
Chu, E. 143–148, 150–153, 155, 160–162, 165, 178
Chubb, C. B. 75, 82
Church, J. 215–216, 225
Cichowicz, D. J. 368, 380
Cidlowski, J. A. 284, 301
Cinti, C. 101, 112
Claesson-Welsh, L. 131, 139
Clapham, P. P. 325, 345
Clapham, P. R. 336, 338, 346
Claret, M. 115, 136
Clark, A. 216, 225
Clark, M. 59, 70
Clarke, D. 85
Clarke, D. J. 85–86, 96
Clarke, S. 201, 203, 222–223
Classen, E. 338, 347
Clements, G. 336, 346
Clements, G. J. 336, 338, 346
Climent, I. 11, 14
Coburn, J. W. 307, 323
Cocco, L. 33–34, 54, 101–107, 109–110, 112–113, 133, 140
Cochet, C. 132, 139
Cockcroft, S. 129, 132, 138–139
Cognet, M. 214, 217–218, 225–226
Cohen, A. S. 307, 323
Cohen, G. M. 288, 302
Cohen, J. 68, 71
Cohen, J. S. 287, 302
Cole, S. P. C. 17–23, 26–28
Coleman, R. 357, 363
Coleman, T. 203, 223
Collart, F. R. 75–76, 79, 82–83
Colman, P. D. 368, 380
Colnaghi, M. I. 365, 379
Colonno, R. 11, 14
Comparsi, R. 22, 29
Connolly, T. M. 250, 255, 263–264
Connor, J. D. 75, 83
Connors, L. H. 307, 323
Conrad, A. H. 165, 178
Conrad, S. E. 153, 162
Conricode, K. M. 387, 405
Cook, J. S. 368, 380
Cook, S. J. 387, 405
Cooke, F. T. 131, 139
Cooper, C. L. 115, 128, 135
Cooper, J. A. 172, 180
Copur, S. 145–146, 160
Copur, S. M. 155, 162, 165, 178
Corbett, T. H. 145, 160
Corkey, B. E. 231, 243
Cornet, M. E. 397, 406
Cory, A. H. 3, 11, 13
Cory, J. G. 3–7, 10–11, 13–15
Cosentino, G. 4, 11–13
Costa, S. D. 386,403
Costabel, U. 386, 404
Coste, H. 259, 264
Coughtrie, M. W. H. 85–86, 96
Couglin, S. R. 396, 405
Coupe, C. 202, 205, 223
Courtneidge, S. A. 123, 137–138
Coury, L. 66, 69, 71
Cowan, K. H. 153, 162
Coward, J. K. 367, 375, 379
Craig, W. 157, 163
Crane, R. 211, 224
Crawford, D. H. 336, 346

Cress, W. D. 298, 303
Crompton, M. 187, 198
Croop, J. M. 352, 362
Crosby, R. 386, 403
Crossley, P. H. 165, 178
Crowell, P. L. 386, 403
Cuello, A. C. 241, 244
Cuif, M. 214, 225
Cuif, M.-H. 208, 217, 224–225
Cumme, G. A. 116, 136
Cunningham, D. 143, 159
Cunningham, E. 129, 132, 138–139
Curtin, G. 39, 41, 55, 133, 140
Cushman, S. 199, 221
Cvitkovic, E. 386, 402
Cyjon, A. 75, 83
Czyzyk, L. 157, 163

D'Auito, G. 269, 280
Dale, I. L. 386, 403
Dalgarno, D. C. 124, 138
Dalgleish, A. G. 325, 336, 345–346
Danenberg, K. D. 145, 160
Danenberg, P. V. 143, 145, 152, 159–161
Danielpour, D. 291, 302
Danserau, M. 4, 11–13
Darzynkiewicz, A. 288, 302
Das, P. 124, 138
Datto, M. B. 298, 303
Davenport, R. 387, 405
Davies II, J. F. 153, 162
Davies, J. A. 237, 243
Day, A. 386, 404
Dayton, J. S. 75–76, 78–80, 83–84
Dazin, P. 297–298, 302
De Blasi, A. 110, 113
De Graan, P. N. E. 115–116, 118, 120, 135–136
De Haan, J. 21, 24, 29
De Haas, M. 17–18, 23, 27
De Haseth, P. L. 152, 161
De Laat, S. W. 133, 139
De Vries, E. G. E. 17–18, 20, 23, 27–28
De Vries, K. J. 115, 136
De Vries-Smits, A. M. M. 133, 139
De Wit, E. C. M. 360, 363
De Wit, I. S. C. 110, 114
Dean, N. M. 248, 263
Debbas, M. 292, 297, 302
Debose, C. 66, 69, 71
Debriec-Rychter, M. 110, 113
De Caprio, J. A. 289, 302
Decaux, J.-F. 208, 223
Decker, S. J. 386, 403
Deeley, R. G. 17–23, 26–28
Defusco, P. A. 144, 160
Degraw, J. I. 367, 379
De Gregori, J. 299, 303
Dekker, H. 17, 22, 27
Del-Rosario, M. 400, 407
Delcamp, T. J. 153, 162
Delzenne, N. 216–218, 225
Demuth, L. 386–387, 389–390, 392–393, 396, 400, 404
Den Hartigh, J. C. 115, 132, 136
Dent, P. 387, 405
Denton, R. M. 183–198
Depinho, R. A. 298, 303
Derewenda, Z. 59, 65, 70
Detheux, M. 208, 213, 224
Deuter-Reinhard, M. 123, 137
Deutscher, M. P. 308, 323
Devron, R. 9–10, 14
Dewald, D. B. 124, 126, 128, 138
Dhand, R. 123–124, 137–138
Di Pietro, R. 110, 113
Diaz Meco, M. T. 387, 405
Diaz-Guerra, M.-J. 207–211, 214–215, 217, 223–225
Diaz-Laviada, I. 397, 406
Diaz-Meco, M. T. 397, 406
Diekmann, D. 130, 139
Diggle, T. A. 183, 192–105, 198
Dillon, S. 131, 139
Dimitrov, N. 144, 160
Dina, D. 342, 347
Dingemans, K. P. 360, 363
Diraimondo, C. R. 320, 323
Distler, A. 319, 323
Divecha, N. 101, 105,109–110, 112–113, 115–116, 119–120, 122, 124, 133, 135–137
Divgi, C. R. 386, 402
Dixon, J. F. 229–230, 240–244, 246, 250, 260, 262, 264
Dobrusin, E. M. 386, 403
Docherty, K. 216, 225
Dodge, J. 386, 404
Dodson, E. 59, 65, 70
Doiron, B. 208, 224
Dolnick, B. J. 165, 167–168, 170–171, 178–179
Domin, B. A. 153, 162
Dominguez, I. 387, 405
Doppler, W. 390–391, 396, 405, 407
Doskeland, S. O. 289, 302
Downes, C. P. 241, 244, 246, 262
Downes, D. L. 3
Drake, J. C. 143–147, 150–151, 159–161, 165, 178
Dreher, K. 211, 224
Dryden, P. 387, 405
Dube, S. K. 170, 179
Duceppe, J.-S. 4, 11–13

Duckworth, B. 385, 402
Duee, P.-H. 201–202, 222
Duhamel, L. 259, 264
Duncan, A. M. V. 17, 18, 23, 27
Dunlap, R. B. 152, 161
Durand, G. 91, 94, 97, 201, 223
Dyke, R. W. 367, 379

Earp, H. S. 257, 264
Eberhard, D. A. 115, 128, 135
Eberle, M. 131, 139
Eble, J. N. 35, 55
Ebner, T. 86, 88, 96
Eckhardt, S. 35, 55
Eckler, C. L. 336, 346
Edgell, N. J. 183, 192–194, 198
Egan, E. F. 144–145, 160, 165, 178
Egan, S. E. 279, 281
Egan, W. 68, 71
Egorin, M. J. 386, 402
Eguinoa, A. 131, 139
Ehninger, G. 22, 29
Ehrlich, C. E. 35, 55
Eibl, H. 387, 405
Eichinger, H. 386, 404
Eijdems, E. W. H. M. 17–18, 23, 27, 352, 361
Einhorn, J. 375, 380
Eisenberger, M. A. 386, 402
Ekhart, P. F. 115, 120, 136
El-Sayed, M. 66, 69, 71
Elder, P. K. 77, 83
Elion, J. 91, 94, 97
Ellis, C. 400, 406
Ellis, P. 143, 159
Ellis, S. 309, 323
Ellis, Y. 237, 243
Elwood, C. 165, 178
Elwood, P. C. 146–147, 150, 161
Emerick, A. W. 123, 137
Emmons, S. S. 309, 323
Emr, S. D. 123–124, 126, 128, 137–138
Emrani, J. 36, 55
Endicott, J. A. 352, 361
Endo, S. 110, 113
Engel, D. 170, 179
Engel, J. 398, 406
England, P. J. 185, 187, 197
Enserink, M. 21, 29
Entenman, C. 356, 363
Eppenberger, U. 386, 403
Erdjumetn-Bromage, H. 123, 137
Escobedo, J. 400, 407
Esposito, G. 269, 280
Estes, M. 353, 362
Ettinger, R. S. 401, 407
Eulitz, M. 320, 323
Evans, J. P. M. 75, 82
Evans, T. 131, 139
Evarts, R. P. 353, 362
Exton, J. H. 115, 135, 387, 397, 400, 405–407
Exton, S. H. 387, 397, 405

Fabbro, D. 386–387, 403, 405
Faenza, I. 101, 112
Fain, J. N. 241, 244
Falck, J. R. 115, 135
Fan, G. 283, 291, 294, 296, 302
Farr, A. L. 36, 55, 88, 96, 309, 323
Fauq, A. H. 386, 404
Fausst, S. 91, 94, 97
Fausto, N. 26, 29, 291, 302
Feig, L. 131, 139
Feig, S. 230, 243
Felder, C. C. 386, 400, 404, 407
Feldman, E. L. 246, 263
Fell, D. A. 35, 55
Feller, N. 22, 29
Feng, S. 124, 138
Fennell, M. 241, 244
Fenves, A. 307, 323
Feramisco, J. R. 289, 302, 396, 405
Fernandes, D. J. 76, 83
Fernandez-Checa, J. C. 18, 28
Ferre, P. 199, 201–207, 210, 216–218, 220, 222–223, 225–226
Fesik, S. W. 115, 135
Fevery, J. 21, 29, 87, 96
Fidler, I. J. 267, 274, 280
Filhol, O. 132, 139
Financsek, I. 75, 83
Finer-Moore, J. S. 143, 159
Fink, E. 333–334, 345–346
Finkenzeller, G. 387, 405
Finlay, C. A. 155, 162
Fisette, P. L. 115–116, 118–121, 129, 132, 135–136
Fisher, B. 144, 160
Fisher, E. R. 144, 160
Fisher, S. K. 250, 263
Fitzgerald-Hayes, M. 128, 138
Flanagan, C. A. 123, 137
Flatmark, T. 115, 130, 136
Fleer, E. A. M. 387, 405
Fleischer, A. E. 4, 11, 14, 15
Flick, J. S. 128, 138
Fluharty, A. L. 309, 323
Fojo, A. 353, 362
Fontana, J. A. 386, 402
Fonti, R. 269, 280
Fornace, A. J. 157, 163

Fornaro, M. 365, 379
Fossum, R. D. 386, 403
Fouchier, R. A. M. 338, 347
Foufelle, F. 199, 201–207, 210–211, 216–218, 222–223, 225
Foulkes, W. D. 365, 379
Foulstone, E. J. 192–194, 198
Fournier, T. 91, 94, 97
Frahm, J. 260, 264
Fraker, D. L. 144, 160
Franco, C. T. 170, 179
Francois, E. 143, 159
Frangione, B. 320, 323
Fraser, K. 17, 27
Freed, E. O. 336, 346
Freer, R. 386, 404
Frei, C. 123, 137
Freisheim, J. H. 153, 162, 365–366, 379
French, C. L. 77, 83
Freund, S. 22, 29
Friedkin, M. 143, 159
Friedmann, A. 215–216, 225
Frijters, C. M. G. 351
Frith, D. 387, 405
Frits, H. 333–334, 345–346
Fritsch, E. F. 165–166, 168, 178, 355, 363
Fritz, R. 211, 224
Frosing, R. 145, 160
Frunder, H. 116, 136
Fry, M. J. 123–124, 137–138
Fujimoto, A. 309, 323
Fujita, T. 283, 301
Fukami, K. 115, 129, 132, 135–136
Fukuda, H. 201, 211–212, 222, 224
Fukuma, T. 337, 346
Fukutomi, A. 325–328, 336–337, 345
Fulco, A. 91–92, 94, 97
Funato, T. 386, 403
Fung, Y.-K. T. 297–298, 302
Furihata, C. 268, 274, 280
Furler, S. 211–212, 224
Futatsuki, K. 143–144, 159

Gandemer, G. 201, 223
Gani, D. 246, 262
Gant, T. W. 353, 362
Garcia-Bustos, J. F. 123, 137
Garfin, D. E. 308, 323
Garigapati, V. 60, 62, 70–71
Garrido, J. 353, 362
Garsky, V. 11, 14
Gascard, P. 115, 136
Gasic, G. 218, 226
Gassen, H. G. 333, 346
Gates, S. B. 365–367, 371, 379–380
Gatmaitan, Z. 18, 28, 351, 361
Gaudiano, G. 22, 29
Gauldie, S. D. 17, 23, 27
Gauss, P. 150, 161
Gauthier, F. 338, 347
Gazdar, A. 171, 179
Gee, N. S. 246, 262
Geilen, C. C. 387, 405
Gejo, F. 307, 320, 323–324
Gekeler, V. 18, 22, 27
Geng, D. 57
Gentry, L. E. 365–366, 379
George, E. L. 4, 7, 10, 13
George, S. 298, 303, 368, 380
Gerlach, J. H. 17, 18, 23, 27
Gerlt, J. A. 168–169, 179
Gershengorn, M. C. 116, 136
Gescher, A. 386, 403
Getz, M. J. 77, 83
Gibbs, J. B. 386, 403
Gibson, W. 367, 379
Giddings, B. W. 279, 281
Gierschik, P. 123, 137
Gijnovci, A. 199, 205, 222
Gil, J. 205, 223
Gilbert, H. S. 375, 380
Gill, G. N. 132, 139
Gilman, A. 365, 378
Gilmer, T. 386, 403
Gilmour, R. S. 33–34, 54, 101–107, 109–110, 112–113, 133, 140
Girard, J. 199, 201–207, 210–211, 220, 222–223, 226
Giraud, F. 115, 136
Gish, B. G. 229, 243
Gispen, W. H. 115–116, 118, 120, 135–136
Gjertsen, B. T. 289, 302
Gluckman, J.-C. 336, 346
Godwin, A. 400, 406
Goebl, M. 123, 128, 137
Goforth, R. 203, 223
Gold, L. 150, 161
Goldhoorn, B. 94, 97
Goldman, I. D. 365, 379
Goldsmith, M. E. 153, 162
Goodman, L. S. 365, 378
Goodman, M. D. 320, 324
Goodman, R. 218, 226
Goodno, C. 59, 70
Gorczyca, W. 288, 302
Gores, G. J. 284, 301
Gorina, S. 386, 404
Gorman, C. M. 88, 97
Gossett, L. S. 367–369, 379, 380
Gottesman, M. M. 17, 27, 352–353, 361–362
Gouhot, B. 201–207, 210–211, 222–223

Gould, M. N. 386, 403
Gout, I. 123–124, 137–138
Gprevic, P. D. 320, 323
Gralla, R. 386, 402
Grand-Perret, T. 259, 264
Granner, D. 199, 205, 222
Grant, C. E. 17–19, 23, 27–28
Graslund, A. 4, 7–10, 14
Gratas, C. 386, 404
Gratton, F. 357, 363
Gray, J. W. 172, 179
Greaves, M. F. 336, 346
Green, M. 143, 159, 386, 403
Greenbaum, A. 200, 222
Gregor, P. 216–217, 225
Gregori, X. 209, 224
Gregory, T. 337, 346
Grem, J. L. 144, 153, 160, 162
Griep, A. E. 284, 301
Griffith, D. 246, 262
Griffith, O. 59, 62, 70
Grill, S. P. 153, 162
Grindey, G. B. 365–367, 369, 371, 376–377, 379–381, 386, 404
Grindon, Y. 4, 11–13
Groen, A. K. 18–19, 21, 28, 351–352, 355–356, 360, 336–363
Grogan, L. M. 143–144, 159
Grondin, P. 115, 136
Groner, B. 386, 390, 396, 403, 405
Groopman, J. E. 337, 346
Groot, K. 386, 402
Groothuis, G. M. M. 18–19, 21, 28
Gros, P. 352–353, 362
Gruest, J. 336, 346
Grunberg, S. M. 367, 379
Grunicke, H. H. 385–387, 389–393, 396, 403–405, 407
Grupposo, P. A. 291, 302
Grutter, M. G. 333, 345
Grynkiewicz, G. 391, 407
Grynspan, F. 246, 263
Gu, J. J. 75
Guadagno, S. N. 387, 405
Guddal, P. H. 397, 406
Guetard, D. 336, 346
Guhlmann, A. 21, 29
Guild, N. 150, 161
Gusovsky, F. 400, 407
Gustavsson, B. G. 145, 160
Gutking, J. S. 400, 406

Haas, N. 400, 406
Haas-Kogan, D. A. 297–298, 302
Haase, R. 387, 405
Habeck, L. L. 365, 367–369, 379–380
Hager, P. W. 76, 79, 82–83
Hagiwara, M. 218, 226
Hahn, U. 68, 71
Haile, W. H. 171, 179
Hajdu, J. 387, 405
Hajduk, P. J. 115, 135
Hajnoczky, G. 187–188, 198
Hakanishi, H. 115, 135
Hakomori, S. 272, 280
Halban, P. 207, 223
Halestrap, A. P. 183–187, 196–197
Hall, A. 130–131, 133, 138–139
Hall, M. M. 123, 137
Hall, M. N. 123, 137
Hall, P. W. 320, 323
Hallcher, L. M. 246, 262
Halmos, G. 386, 402
Hamada, H. 352, 361
Hamelin, J. 91, 94, 97
Hamilton, A. D. 386, 403
Hamilton, J. M. 144, 160
Hamilton, R. 19, 21–22, 28
Hampl, H. 320, 323
Hanchett, L. A. 168, 179
Hanck, T. 123, 137
Hande, K. 19, 21–22, 28
Hanicke, W. 260, 264
Hanks, S. K. 124, 138
Hanley, M. R. 246, 262
Hanrahan, A. 143, 159
Hanse, S. 59, 70
Hansen, L. 59, 65, 69–71
Hansen, S. 59, 65, 69–71
Hansen, S. I. 370, 380
Hansford, R. G. 187–188, 197
Hanson, P. I. 400, 407
Harden, T. K. 257, 264
Hardenbrook, C. 18, 28
Hardie, D. 200, 222
Hardonk, M. J. 21, 29
Hardy, L. W. 143, 159
Harford, J. B. 153–154, 162
Harlan, J. E. 115, 135
Harlow, E. 167–168, 179
Harmon, J. 215–216, 225
Harootunian, A. T. 396, 405
Harris, C. C. 155, 163
Harwerth, I. M. 386, 403
Hashimoto, Y. 36, 55
Hasson, M. S. 168–169, 179
Hattori, T. 325, 336–337, 345
Haupt, Y. 297–298, 303
Hauser, G. 246, 257, 263–264
Havinga, R. 21, 29
Hawkins, P. T. 116, 124, 131, 138–139
Hay, J. C. 115, 128–129, 132, 135, 138
Hay, R. T. 387, 405

Hayashi, F. 130, 139
Hayashi, K. 18, 28
He, J. S. 91–92, 94, 97
Heacock, A. M. 250, 260, 263–264
Heerema, N. 75, 83
Heesom, K. J. 192–194, 198
Hegewald, H. 116, 136
Heidecker, G. 387, 405
Heidelberger, C. 145, 160
Heimer, R. 165, 178
Heinemann, U. 68, 71
Heinzel, 333, 346
Heirwegh, K. P. M. 87, 96
Heitzman, K. J. 171, 179
Helene, C. 386, 403
Helliwell, S. B. 123, 137
Helms, B. 110, 114
Helms, J. B. 115, 136
Helson, L. 246, 262
Hemanta, K. 199, 221
Henderson, B. R. 154, 162
Henderson, G. H. 365, 378
Henquin, J. C. 205–206, 223
Henriquez, R. 123, 137
Henry, S. 171, 179
Hensey, C. 387, 398, 404
Henslee, J. G. 171, 179
Hentze, M. W. 151, 153, 161
Hepler, J. R. 257, 264
Hercent, T. 336, 346
Herenyiova, M. 33, 35–36, 39, 43, 48, 55
Herman, P. K. 123, 137
Herrick, D. J. 155, 162
Herrup, K. 284, 301
Hers, H. 199, 222
Hershey, J. W. B. 151, 153, 161
Heuman, D. 360, 363
Hiles, I. 123, 129, 138
Hiles, I. D. 123–124, 137–138
Hilgard, P. 386, 398, 404, 406
Hinchliffe, K. A. 122, 124, 137
Hinds, P. W. 283, 301
Hines, J. D. 165, 178
Hinrichs, W. 68, 71
Hipfner, D. R. 17, 19, 23, 27–28
Hirasawa, M. 307, 323
Hirsch, H. E. 309, 323
Hitier, Y. 202, 205, 223
Hoch, J. 201, 222
Hockenbery, D. 292, 297, 302
Hoekman, M. Fm. 360, 363
Hoffbrand, A. V. 75, 82
Hoffman, B. 298, 303
Hoffman, R. 75–76, 82–83
Hofmann, J. 391, 407
Hokin, L. E. 115–116, 135, 229–230, 240–246, 248–250, 253–254, 256, 260, 262–264
Holeck, B. U. 110, 113
Hollan, S. R. 102, 104, 112
Hollstein, M. 155, 163
Holm, J. 370, 380
Holmes, K. A. 386, 404
Holness, M. J. 184, 196
Holst, H. 68, 71
Holz, R. W. 115, 128, 135
Homa, Y. 133, 140
Homma, M. 325–326, 328, 330, 344–345 345
Homma, N. 320, 324
Honchar, M. P. 229, 243
Hong, M. 144, 160
Hoogstraten, B. 375, 380
Hope, H. 116, 136
Horanyi, M. 102, 104, 112
Hordvik, A. 59, 65, 70
Hori, M. 278, 281
Horie, T. 18, 28
Horiuchi, S. 322, 324
Hoshino, T. 337, 346
Houge, G. 289, 302
Hough, E. 59, 65, 69–71
Houghton, J. A. 377, 381
Houghton, M. T. 365, 379
Houghton, P. J. 377, 381
Housman, D. E. 352, 362
Howard, B. H. 88, 97
Howard, S. 387, 405
Howell, B. 172, 180
Hseueh, C.-T. 165
Hsu, J. 351, 361
Hsu, J.-C. 366, 379
Hsu, M.-H. 85
Hsu, T. 150, 161
Hsuan, J. 124, 138
Hsuan, J. J. 122–124, 132, 137, 139
Hu, N. 284, 301
Hu, P. 123, 137
Huang, C. 190, 198
Huang, C. Y. 11, 14
Huang, S. 286, 301
Huber, B. E. 353, 362
Huber, K. R. 401, 407
Huber, M, 21, 29
Huber, R. 333, 345
Huberman, E. 75–76, 79, 82–83
Hucho, F. 387, 405
Hue, L. 199, 222
Hug, H. 250, 259, 264, 387, 404
Hughes, A. R. 247, 250, 263
Hughes, L. R. 367, 379
Hughes, W. A. 191, 198

Hui, K. Y. 386, 404
Huisman, G. W. 168–169, 179
Hummel, R. 250, 259, 264, 387, 405
Humphries, M. J. 272, 276, 280–281
Hung, D. T. 396, 405
Hunt, T. 4, 7, 10, 13
Hunter, T. 124, 132, 138
Hupp, T. R. 386, 404
Hurd, S. D. 400, 406
Husebye, E. S. 115, 130, 136
Huskisson, N. S. 105, 113
Hylemon, P. B. 360–361, 363
Hynes, N. E. 386, 403

Ichikawa, K. 123, 137
Iinuma, H. 272–274, 281
Iitaka, Y. 272, 281
Ikegami, T. 36, 55, 102, 104, 112
Ikezawa, H. 59, 70
Imaizumi, A. 333, 346
Imoto, M. 276, 281
Inagami, T. 397, 406
Inagi, R. 322, 324
Ingrisch, H. 333, 345
Inokuchi, J. 272, 280
Inoue, M. 337, 346
Inui, H. 397, 406
Irino, S. 75–76, 82
Iritani, N. 201, 211–212, 222, 224
Irvine, R. F. 101, 105, 109–110, 112–113, 115–116, 119–120, 122, 124, 133, 135–137, 391, 407
Ise, W. 18, 22, 27
Ishii, S. 269, 280
Ishikawa, T. 18, 21–22, 28–29
Israel, M. A. 297–298, 302
Issad, T. 202, 211, 223
Ito, M. 153, 162
Itoh, O. 278, 281
Ives, H. E. 400, 407
Iyanagi, T. 85, 96
Iynedjian, P. 199, 205, 207, 209–211, 222–223

Jackman, A. L. 165, 178, 367, 379
Jacks, T. 298, 303
Jackson, M. R. 86, 96
Jackson, R. C. 75, 82
Jackson, R. G. 246, 262
Jackson, S. 219, 226
Jackson, T. R. 116, 124, 131, 138–139
Jacobs, S. C. 386, 402
Jacobs, W. 386, 404
Jaggi, R. 391, 407
Jaknun, J. 386–387, 389–390, 392–393, 396, 400, 404
Jakowlew, S. B. 291, 302
Jamis-Dow, C. A. 145, 160
Janjic, D. 207, 223
Janmey, P. A. 115, 122, 130–131, 135
Jannatipour, M. 367, 379
Jansen, P. 18, 28, 94, 97
Jansen, P. L. 85, 96
Jansen, P. L. M. 18–21, 24, 28–29, 86, 96
Jarai, G. 75, 83
Jaroszewicz, K. 116, 136
Jaumann, E. 333, 345
Javaherian, K. A. J. 336, 346
Jayaram, H. N. 75, 83
Jeanrenaud, B. 212, 225
Jedlitschky, G. 17–28
Jeffrey, P. D. 386, 404
Jelinek, D. F. 360, 363
Jellis, A. T. 336, 346
Jenh, C. H. 145, 160
Jenkins, A. 211–212, 224
Jenkins, G. H. 115–116, 118–121, 129, 132, 135–136
Jenkinson, S. 246, 262
Jensen, T. J. 26, 29
Jergil, B. 34, 54
Jian, D. 283, 301
Jiao, L. 386, 403
Jimbo, M. 272, 280
Jirtle, R. 292, 297, 302
Jochimsen, P. 144, 160
Jodrell, D. I. 386, 402
Johansen, T. 397, 406
Johnson, B. E. 171, 179
Johnson, D. G. 298, 303
Johnson, E. F. 85
Johnson, L. F. 145, 160, 165, 178
Johnston, C. L. 130, 139
Johnston, P. G. 143, 145–146, 148, 159, 161, 171, 179
Jolivet, J. 153, 162
Jones, D. 283, 301
Jones, G. A. 116, 140
Jones, J. 144, 160
Jones, K. 387, 405
Jones, K. L. 152, 155, 162, 165, 178
Jones, M. O. 143, 159
Jones, T. A. 365, 379
Jongsma, A. P. M. 352, 362
Jope, R. S. 229, 243
Jordan, S. 386, 403
Jorgensen, F. 59, 70
Joshi, V. 201, 222
Judson, R. 367, 379
Jump, D. 201, 215, 222, 225
Jynge, K. 59, 65, 70

Kaback, H. 199, 221
Kaelin Jr., W. G. 287, 299, 302–303
Kahn, A. 207–215, 217–218, 223–226
Kahn, R. A. 129, 138
Kambe, M. 143–144, 159
Kamen, B. A. 365, 378
Kamimoto, Y. 18, 28, 351, 361
Kamimura, T. 333, 346
Kanai, Y. 268, 274, 280
Kanba, S. 250, 263
Kaneda, S. 145, 160, 165, 178
Kanzaki, N. 79, 84
Kapeller, R. 385, 402
Kaplowitz, N. 18, 28
Karam, J. 150, 161
Kardinal, C. G. 144, 160
Karnes Jr, W. E. 172, 180
Kartenbeck, J. 18–21, 23–28
Kartner, N. 26, 29
Kashani-Sabet, M. 386,403
Kastan, M. B. 157, 163
Kasuga, M. 123, 138
Kataoka, H. 307, 323
Kato, M. 255, 264
Kato, R. 123, 137, 250, 263
Katsurada, A. 201, 211, 222, 224
Katunuma, N. 325–328, 336–337, 345
Katz, H. 123, 137
Kauffmann-Zeh, A. 132, 139
Kaushansky, K. 77, 83
Kawada, M. 270–271, 280
Kawaguchi, Y. 328, 345
Kawamura, M. 307
Kawasaki, H. 80, 84
Kay, J. 336, 338, 346
Kaysen, J. 220, 226
Kazlauskas, A. 400, 406
Kazmi, S. M. I. 246, 263
Keith, C. T. 123, 137
Keller, F. 319, 323
Keller, K. 190, 198
Kelly, T. J. 153, 162
Kemme, M. 333, 346
Kendall, D. A. 229, 243
Kennedy, E. D. 229, 240, 243, 246, 262
Kenyon, G. L. 168–169, 179
Keppler, D. 17–23, 26–29
Kerbey, A. 220, 226
Kerler, R. 110, 113
Kerr, D. J. 385, 402
Kessar, P. 187, 198
Keyomarsi, K. 145, 160
Khan, C. R. 192, 198
Khan, K. M. F. 308, 323
Kharbanda, S. M. 75, 80, 83
Kido, H. 325–328, 331, 335–337, 345–346
Kihara, H. K. 309, 323
Kikkawa, U. 387, 404
Kilburn, E. 200, 222
Kim, J.-S. 366, 379
Kim, K. 200, 222
Kim, K.-H. 207–208, 210–212, 220, 223
Kim, S.-J. 283, 301
Kimball, R. 367, 379
Kimery, M. 386, 403
Kimura, S. 86, 96, 201, 223
Kinder, D. 386, 403
Kindler, E. 385–386, 404
King, K. K. 356, 363
King, K. L. 284, 301
King, W. G. 131, 139
Kinlaw, W. 215–216, 225
Kinoshita, T. 322, 324
Kinter, M. 190, 198
Kinzler, K. W. 155, 162
Kirilovsky, J. 259, 264
Kirschke, H. 309, 323
KiserHartwell, L. H. 123, 137
Kishi, Y. 60, 70
Kishimoto, A. 387, 303
Kishino, Y. 326, 328, 335, 345
Kisliuk, R. L. 152, 161
Kitamura, T. 18, 28
Klatzmann, D. 336, 346
Klausner, R. D. 153–154, 162
Klein, H. 201, 222
Klein, W. 217, 225
Klenk, H.-D. 328, 345
Klenk, H.-K. 325, 328, 344
Klenner, T. 386, 398, 404, 406
Kletzien, R. 211, 224
Klietzen, R. 211, 224
Klippenstein, G. L. 11, 15
Klunemann, C. 18, 21, 28
Kneebone, P. 75, 83
Knofler, M. 153, 162
Knopf, J. 400, 406
Knudsen, E. S. 283, 301
Kobayashi, K. 18, 28
Koch, M. O. 400, 406
Koch, T. H. 22, 29
Kochs, G. 250, 259, 264, 387, 405
Koeller, D. M. 145–148, 150–151, 160–161, 165, 178
Koffer, A. 130, 138–139
Kogan, S. C. 297–298, 302
Kohl, N. E. 386, 403
Kohn, E. C. 386, 400, 404, 407
Kohn, E. K. 386, 404
Kohri, T. 328, 345
Koito, A. 325, 336–337, 345
Kojima, K. 133, 140
Kojiri, K. 276, 281
Kok, J. W. 115, 135

Kokileva, L. 284, 301
Kolch, W. 387, 405
Kolter, R. 168–169, 179
Kondo, T. 397, 406
Konishi, F. 397, 406
Konno, Y. 75–76, 80, 82–84
Koontz, S. W. 152, 161
Kornberg, A. 143, 159
Koropatnich, S. E. 10, 14
Korsmeyer, S. 292, 297, 302
Koshland, D. 124, 126, 128, 138
Kostrewa, D. 68, 71
Kote, Z. 75, 83, 102, 104, 112
Kour, G. 387, 405
Kovesdi, I. 298, 303
Kowalik, T. F. 299, 303
Koyama, H. 145, 160, 165, 178
Koyano, T. 279, 281
Kozak, M. 151, 153–154, 161
Kozikowski, A. P. 386, 404
Kozlowski, M. 217, 225
Kragen, E. 211–212, 224
Kramps, J. A. 333, 345
Kraup-Grasl, B. 292, 297, 302
Krauss, R. S. 387, 405
Kraut, J. 153, 162
Krebs, E. G. 183–184, 196
Krebs, H. A. 34, 35, 54, 55
Kremmer, T. 102, 104, 112
Kren, B. T. 291, 294, 296, 302
Kris, M. 386, 402
Krishnamachary, N. 17, 19, 23, 27
Krueger, J. G. 172, 179
Kudlow, J. 210, 224
Kufe, D. W. 75, 80, 83
Kuhn, J. C. 154, 162
Kuhnt, D. 367, 379
Kuipers, F. 18–21, 28–29
Kung, H. F. 400, 406
Kung, W. 386, 403
Kunisawa, R. 123, 137
Kunitomo, T. 307, 323
Kunst, M. 18, 28
Kunz, J. 123, 137
Kuo, J. F. 387, 405
Kuo, M. T. 353, 362
Kuo, W.-L. 172, 179
Kuppe, A. 59, 62, 70
Kuroiwa, S. 278, 281
Kurz, E. U. 17, 18, 23, 27
Kutscher, B. 398, 406
Kwiatkowska, K. 130, 138
Kwok, R. 218, 226
Kyriakis, J. M. 192, 198

Lacey, S. W. 365, 378
Laemmli, U. K. 168, 179, 308, 323
Lagerlof, B. 375, 380
Lai, C.-C. 284, 301
Laiho, M. 289, 302
Lajtha, A. 255, 264
Lakatta, E. G. 187–188, 197
Lakshmanan, M. 201, 222
Laman, J. D. 338, 347
Lamb, T. 218, 226
Lambert, D. G. 246, 250, 255–256, 262–263
Lamers, W. H. 21, 29
Lamorte, V. J. 396, 405
Lancet, D. 85, 96
Lane, D. 167–168, 179
Lane, D. P. 386, 404
Lane, W. S. 123, 137
Lange, A. J. 87, 96
Langedijk, J. P. M. 338, 347
Langlois, A. J. 338, 346
Langlois, C. 336, 346
Lankelma, J. 17, 22, 27
Lanotte, M. 289, 302
Lantley, L. C. 385, 402
Lantz, R. J. 367, 380
Laohavinij, S. 367, 375, 380
Lapis, E. 75, 83
Lapoumeroulie, C. 91, 94, 97
Larner, J. 190, 198
Larocca, R. V. 386, 402
Larrodera, P. 397, 406
Larson, S. M. 386, 402
Larsson, C. 250, 263
Laurent, G. 320, 323
Lavalle, P. 4, 11–13
Lawetz, C. 4, 11–13
Lawler, A. 368, 380
Lawson, J. E. 195, 198
Layer, R. T. 241, 244
Le Trong, H. 195, 198
Lea, M. A. 35, 49, 54
Leary, R. P. 152, 161
LeBlanc, J. 284, 301
Lee, C.-S. 133, 139
Lee, C. H. 229–230, 240–243, 246, 262, 355, 362
Lee, E. Y.-H. P. 284, 301
Lee, H. 60, 70
Lee, K. 59, 70
Lee, W.-H. 283–284, 299, 301, 303
Leech, A. 209, 213, 224
Lefrancois-Martinez, A.-M. 208, 217, 224, 226
Lehman, E. J. 360, 363
Leichman, C. G. 367, 379
Leier, I. 17–28
Leitner, T. A. 367–369, 379, 380
Leli, U. 246, 257, 263–264

Lemaigre, F. 220, 226
Lemas, V. 75, 83
Lepetit, N. 216–218, 225
Lepine-Frenelty, C. 4, 11–13
Lerner, M. R. 147, 155, 161
Letcher, A. J. 101, 112, 115, 133, 136
Leveille, C. 18, 28, 351, 361
Levi, D. 297–298, 302
Levine, A. J. 155, 162, 298, 300, 303
Levine, L. 59, 70
Levine, R. 153, 162
Levitt, L. 77, 83
Levitzki, A. 385–386, 402–403
Levrat, F. 217–218, 226
Levy, J. 342, 347
Levy, J. A. 336, 338, 346
Levy, R. B. 400, 406
Lewis, G. K. 338, 347
Lewis, K. 60, 62, 71
Lewis, S. 376, 381
Lewis, W. H. 10, 14
Li, D. 165, 178
Li, G. 207, 223
Li, P. Y. 269, 280
Li, Y. 165, 178
Liang, C.-M. 171, 179
Liang, Q. 91–92, 94, 97
Lida, Y. 322, 324
Liebermann, D. A. 298, 303
Liefting, W. 21, 24, 29
Liepkalns, V. A. 246, 263
Limatola, C. 397, 406
Lin, B.-F. 366, 379
Lin, H.-K. 298, 303
Lin, L. L. 400, 406
Lin, Q. 217, 225
Lin, S. 386, 403
Lincke, C. R. 352, 362
Lindhout, D. 94, 97
Lindsten, T. 75, 80, 83
Ling, L. E. 115, 119, 136
Ling, V. 352, 355, 361–362
Linke, R. P. 320, 323
Liotta, L. A. 386, 404
Lippman, M. E. 144–145, 160, 165, 178
Lipton, P. 230, 243
Liscovitch, M. 115–116, 129, 132, 135, 138, 400, 407
Little, C. 59, 65, 70
Little, P. F. R. 165, 178
Liu, Z. 214, 217–218, 225–226
Livanos, E. M. 292, 302
Livingston, D. M. 287, 289, 299, 302–303
Liyanage, M. 387, 405
Lledo, P.-M. 255, 264
Lodish, H. 199, 221
Loe, D. W. 17, 27
Lohr, G. W. 386, 404
Loijens, J. C. 115
Look, K. Y. 33–36, 43, 47–48, 54–55
Lopez-Barahona, M. 397, 406
Lorente, P. 369, 380
Loriolle, F. 259, 264
Los, G. V. 229–230, 240–246, 248–249, 253–254, 256, 260, 262–264
Lottspeidt, F. 333, 346
Loubtchenkov, M. 123, 137
Low, M. 59, 70
Low, M. G. 115, 128, 135
Lowe, K. E. 366, 379
Lowenstein, J. M. 231, 243
Lowitt, M. H. 386, 402
Lowry, O. H. 36, 55, 88, 96, 309, 323
Lozano, J. 387, 405
Lu, K. 171, 179
Luciw, P. 342, 347
Luckenbach, G. A. 386, 404
Ludlow, J. W. 289, 302
Lueders, J. E. 400, 407
Luhrs, C. A. 365, 379
Lui, G. K. 246, 263
Lui, M. 123, 137
Lundberg, G. A. 34, 54
Lydon, N. B. 386, 403
Lyerly, H. K. 338, 346
Lyngbye, J. 370, 380
Lyonnet, S. 208, 210, 213, 223

Ma, L. 17, 19, 23, 27
Ma, X. 291, 294, 296, 302
MacDonald, M. 220, 226
MacDonald, R. J. 168, 179
MacDougald, O. 215, 225
Machleidt Jr., W. 333, 346
Mackie, J. E. 17, 18, 23, 27
Maclachlan, L. K. 187, 197
Maddon, P. J. 325, 345
Maeda, K. 322, 324
Mager, W. H. 360, 363
Magnus, E. 375, 380
Magnuson, M. 199, 205, 222
Majerus, P. 200, 222
Majerus, P. W. 34, 54, 101, 110, 112, 133, 140, 250, 255, 263–264
Majoor, D. 352, 362
Makagawa, M. 307, 323
Malek, D. 123, 137
Maley, F. 146, 150–152, 155, 161–162, 165, 178
Maley, G. F. 146, 150–152, 155, 161–162, 165, 178
Maloney, N. A. 307, 323

Maltarello, M. C. 101, 112
Maltzman, W. 157, 163
Maly, K. 385, 386–387, 389–391, 392–393, 396, 400, 404–405, 407
Mamounas, E. P. 144, 160
Maniatis, T. 165–166, 168, 178, 355, 363
Mansell, M. M. 4, 13–14
Mantovani, L. 365, 379
Manzoli, F. A. 101, 105, 110, 112–114
Manzoli, L. 33–34, 54, 101–107, 109–110, 112–113, 133, 140
Maraldi, N. M. 101, 110, 112–113
Marasco, C. J. 386, 404
Marchesi, V. T. 116, 136
Mariash, C. 215–216, 219, 225–226
Mariash, C. N. 284, 301
Marie, J. 400, 407
Marie, S. 207, 209–211, 223
Marini, F. 123, 137
Marino, P. A. 353, 362
Mark, G. E. 387, 405
Markwell, M. A. K. 327, 337, 345
Marme, D. 250, 259, 264, 387, 405
Marmiroli, S. 101, 112
Marsden, M. E. 333, 345
Marsh, M. 336, 338, 346
Marshall, S. 210, 224
Marshall, S. E. 185, 191, 197
Marsters, S. A. 337, 346
Martelli, A. M. 33–34, 54, 101–107, 109–110, 112–113, 133, 140
Martin, B. R. 185, 197
Martin, D. M. 246, 263
Martin, M. 22, 29
Martin, S. 59–60, 65–66, 70–71
Martin, T. F. J. 115, 128–129, 132, 135, 138
Martinez, A. 217, 225–226
Martino-Ferrer, M. D. 338, 347
Massa, O. 269, 280
Massague, J. 289, 302
Masuda, K. 333, 346
Matorin, P. A. 320, 324
Matsui, Y. 128, 138
Matsumara, Y. 201, 211, 222, 224
Matsumoto, K. 272, 276, 280–281
Matsumura, Y. 211–212, 224
Matsushima, T. 268, 274, 280
Matter, A. 386, 403
Matter, W. F. 386, 404
Matteucci, A. 103, 107, 109, 113
Matteuci, A. 33–34, 54
Matthews, T. J. 336–338, 346
Mauad, T. H. 360, 363
Mauco, G. 115, 136
Maurer, H. R. 398, 406
Maury, J. 202–207, 210, 220, 223, 226
Mayer, M. L. 233, 239–240, 243
Mayer, R. 17–21, 23–28
Mazzoni, M. 110, 114
Mazzotti, G. 101, 110, 113
McAtee, N. 144, 160, 386, 402
McClarty, G. A. 10, 14
McClements, W. 11, 14
McCloskey, D. E. 171, 179
McClung, J. 211, 224
McClure, M. O. 336, 338,
McCormack, J. G. 183–187, 190–191, 197
McCormick, F. 133, 139
McDanal, K. L. 336, 346
McDanel, H. 400, 406
McDonald, J. K. 309, 323
McDougal, J. S. 325, 345
McGlynn, E. 386, 403
McGuire, J. J. 171, 179
McGuire, J. J. 366–367, 375, 379
McKeating, J. A. 336, 338, 346
McLain, D. 210, 224
McNamara, D. J. 386, 403
Mead, J. E. 291, 302
Meckelein, B. 333, 346
Meda, P. 207, 223
Medina, W. D. 170, 179
Meegan, R. L. 168, 179
Meek, D. W. 386, 404
Mei, L. 246, 263
Meijer, C. 20, 28
Meijer, D. K. F. 18–19, 21, 28
Meikrantz, W. 284, 31
Meisler, A. I. 172, 179
Mejdoubi, N. 91, 94, 97
Melamed, M. R. 288, 302
Melder, D. 386, 404
Melder, D. C. 386, 404
Meldrum, E. 387, 400, 405
Melefors, O. 151, 153, 161
Melhem, M. F. 172, 179
Menard, S. 365, 379
Mendelsohn, L. G. 365–369, 371, 379–380
Menotti, E. 154, 162
Merboldt, K.-D. 260, 264
Mercer, W. E. 155, 162
Merchant, B. 386, 402
Mett, H. 386, 403
Meusburger, H. 391, 407
Mewes, K. 22, 29
Meyer, D. 250, 259, 264
Meyer, M. 115, 135
Meyer, S. 91, 94, 97
Meyer, T. 386, 403
Michaelis, T. 260, 264
Michalke, A. 353, 362
Michell, R. H. 240, 250, 263–264
Michie, 241, 244

Michiels, J. 94, 97
Midgley, C. A. 386, 404
Midgley, P. J. 184, 197
Midgley, P. J. W. 184–186, 190–191, 197
Miller, J. H. 88, 96
Miller, M. 68, 71
Miller, R. J. 233, 239–240, 243
Milovanovic, S. 386, 402
Minaguchi, J. 307
Miotti, S. 365, 379
Miquerol, L. 207, 209–211, 223
Miralpeix, M. 205, 223
Mirda, D. 400, 407
Mirkin, B. L. 75, 82
Mischak, H. 387, 405
Mishra, R. K. 246, 263
Mitchell, B. S. 75–76, 78–80, 82–84
Mitchell, W. M. 338, 347
Miyagawa, K. 79, 84
Miyajima, N. 167, 178
Miyake, M. 272, 280
Miyata, H. 187–188, 197
Miyata, T. 322, 324
Miyazaki, K. 75, 83
Moccio, D. M. 367, 379
Modest, E. J. 386, 404
Modolell, M. 386, 404
Moertel, C. G. 143–144, 159
Moffat, L. F. 88, 97
Moghrabi, N. 85–86, 96
Mol, C. A. A. M. 352, 356, 362
Molnar, G. 145, 160
Molzahn, M. 319, 323
Momand, J. 155, 162
Momosaki, K. 272, 280
Monaco, M. E. 116, 136
Monaghan, G. 86, 96
Mondino, A. 123, 137
Montagnier, L. 336, 346
Montefiori, D. C. 338, 347
Montero, C. 369, 380
Montfort, W. R. 143, 159
Montminy, M. 218, 226
Mool, W. J. 352, 362
Moolenaar, W. H. 397, 406
Moon, K. H. 102, 113
Moore, J. P. 336, 338, 346
Moran, R. G. 145, 160, 367, 368, 376, 379, 380, 381
Moran, S. 220, 226
Morgenbesser, S. D. 298, 303
Morin, J. 216–218, 225
Moritz, A. 115–116, 118, 120, 135–136
Moroson, B. A. 165, 170, 178–179, 367, 379
Morris, H. P. 36, 45, 55
Morrison, P. F. 152, 162
Morrissey, L. 150, 161
Moscat, J. 387, 405–406
Mosman, T. 389, 405
Mosse, H. 46, 55
Moule, S. K. 183, 192–194, 198
Moummi, C. 229–230, 240–243, 246, 262
Moustaid, N. 203, 223
Movva, N. R. 123, 137
Moyer, J. D. 248, 263
Mrachko, G. T. 168–169, 179
Muallem, S. 130, 138
Mueller, M. 386, 403
Muench, A. J. 165, 178
Muench, A. L. 145, 160
Muggia, F. M. 367, 379
Mukhopadhyay, T. 386, 403
Mulder, G. J. 85, 96
Mulder, N. H. 17–18, 20, 23, 27–28
Muller, E. 116, 136
Muller, M. 18, 20–21, 28, 386, 403
Mullner, E. W. 153, 162
Mumby, M. C. 289, 302
Munder, P. G. 386, 404
Municio, M. M. 387, 405
Munnich, A. 208, 210, 213, 223
Munro, J. B. 4, 14
Munsell, L. Y. 229, 243
Murgia, M. 188–189, 198
Myers, C. E. 386, 402
Myers, D. J. 336, 346

Nagai, M. 75–76, 82–83
Nagamatsu, A. 272, 280
Naganawa, H. 272, 281
Naggert, J. 201, 222
Nagy, P. 353, 362
Nahorski, S. R. 229, 240, 243, 246, 250, 255–256, 262–263
Naismith, A. L. 26, 29
Nakaki, T. 250, 263
Nakamura, H. 272, 281
Nakamura, S. 307
Nakanishi, H. 397, 406
Nakanishi, S. 200, 222
Nakano, A. 123–124, 126, 128, 137–138
Nakao, I. 143–144, 159
Nakatsukasa, H. 353, 362
Nara, P. L. 336, 346
Narayanaswami, V. 18, 28
Narkewicz, M. 202, 205, 223
Natori, Y. 308, 323
Natsumeda, Y. 35–36, 55, 75–76, 79–80, 82–84, 102, 104, 112
Navalgund, L. G. 145, 160, 165, 178
Nebert, D. W. 85, 96

Nelson, D. R. 85, 96
Nelson, R. L. 367, 379
Nepokroeff, C. 201, 222
Neri, L. M. 101–107, 109–110, 112–113, 133, 140
Nervi, F. 353, 362
Nettelbeck, R. 334, 346
Nettesheim, P. 110, 113
Neuberg, R. W. 401, 407
Neufeld, E. J. 34, 54
Nevins, J. R. 298–299, 302–303
Newell, D. R. 367, 375, 380
Newsholme, E. 209, 213, 224
Nichols, B. J. 195, 198
Nichols, C. R. 75, 83
Nicolson, G. L. 385, 402
Nicotera, P. 18, 28
Nievers, M. 101, 110, 112, 115, 133, 136
Nikiforov, T. 333, 346
Nilsson, T. 86, 96
Nimura, Y. 133, 140
Nisen, P. D. 365, 378
Nishida, T. 18, 28, 351, 361
Nishioka, M. 307
Nishizawa, M. 167, 178
Nishizuka, K. 57, 70
Nishizuka, Y. 105, 113, 245, 257, 262, 387, 396, 398, 404
Niu, X.-D. 195, 198
Niwa, Y. 325, 337, 346
Nixon, R. A. 246, 263
Nobes, C. D. 130, 139
Noessner, G. 398, 406
Noguchi, T. 201, 211, 222, 224
Nojima, H. 128, 138
Nomura, M. 150, 161
Noonan, K. E. 352, 362
Nordenberg, J. 75, 83
Norgauer, J. 131, 139
Norman, J. 39, 41, 55, 133, 140
Norman, J. C. 130, 138–139
Nosaka, C. 272–274, 281
Nossner, G. 398, 406
Notenboom, R. G. E. 360, 363
Novogrodsky, A. 75, 83
Novotny, E. A. 400, 406
Nowak, G. 241, 244
Numa, S. 200, 222
Nurnberg, B. 123, 137

Oberhammer, F. 292, 297, 302
Oberhammer, F. A. 288–289, 302
Oberhuber, H. 386–387, 389–393, 396, 400, 404–405
Ochi, Y. 272–273, 276, 281
Odani, O. 322, 324
Odani, S. 307, 323
Oestreicher, A. B. 115, 135
Offerhaus, G. J. A. 352, 356, 360, 362–363
Ogawa, H. 123, 137
Ogawa, N. 143–144, 159
Ogemba, L. 205–206, 223
Ognibene, A. 101–104, 107, 109–110, 112
Ohlsson, K. 333, 346
Ohno, S. 75, 80, 83–84
Ohse, T. 279, 281
Ohtani-Fujita, N. 283, 301
Ohuchi,M. 325, 328, 344
Ohya, Y. 123–124, 126, 128, 137–138
Oie, H. 171, 179
Oishi, K. 387, 405
Okada, M. 308, 323
Olah, E. 33–36, 54–55, 75, 83, 102, 104, 112
Olden, K. 272, 276, 280–281
Oliff, A. 386, 403
Onishi, S. 307, 323
Onyekwere, O. 157, 163
Ookhtens, M. 18, 28
Oostra, B. 94, 97
Openheimer, J. H. 284, 301
Or, E. 400, 406
Ore, L. 144, 160
Oren, M. 297–298, 303
Orfali, K. A. 184, 196
Ormerod, M. G. 288, 302
Orrenius, S. 18, 28
Ortlepp, H. 19, 28
Orzechowski, A. 353, 362
Osborn, K. 165, 178
Osborne, C. B. 366, 379
Oshimura, M. 110, 113
Osifchin, N. E. 283, 301
Osterholz, J. 386, 404
Oswald, A. S. 190, 198
Otani, G. 87, 96
Otsu, M. 123, 137
Ottenhoff, R. 21, 24, 29, 351–352, 355–356, 360, 362–363
Oude Elferink, R. P. J. 17–19, 21–22, 24, 27–29, 94, 97, 351–352, 355–356, 360, 362–363
Out, T. 94, 97
Owens, I. S. 86, 96
Oyasu, R. 110, 113

Page, T. 75, 83
Palka, G. 110, 113
Pan, H. 284, 301

Panayotou, G. 123–124, 137–138
Pandak, W. M. 360–361, 363
Panet, C. 75, 83
Pannuti, F. 22, 29
Papa, S. 110, 113
Papp, E. 76, 79, 82–83
Pardee, A. B. 145, 160
Park, J. 172, 179
Park, J.-H. 77, 83
Park, J. G. 171, 179
Parker, G. J. 115
Parker, P. J. 123, 137, 246, 263, 387, 400, 405
Parra, A. 115, 135
Pascal, G. 201, 223
Pass, H. I. 144, 160
Pastan, I. 17, 27, 352–353, 361–362
Pastor-Anglada, M. 202, 211, 223
Patel, M. 220, 226
Patel, N. 246, 262
Patel, T. 284, 301
Paterson, H. F. 130, 139
Pateson, A. 210, 224
Patterson, A. 210, 224
Paul, I. A. 241, 244
Paulauskis, J. 201, 222
Paulik, E. 102, 104, 112
Paulusma, C. 17, 22, 27
Pavelka, M. 288–289, 302
Pavletich, N. P. 386, 404
Pawson, T. 400, 406
Payne, W. E. 128, 138
Payrastre, B. 101, 110, 112, 115, 118, 132–133, 135–136, 139
Pearce, J. 200, 222
Peers, C. 246, 263
Pegorier, J.-P. 201–202, 222
Peilly, T. J. 309, 323
Peles, E. 400, 406
Peña, S. V. 172, 179
Pennington, K. 75, 83
Peorier, J.-P. 202–207, 210–211, 223
Peppelenbosch, M. P. 133, 139
Perdereau, D. 201–207, 210–211, 222–223
Perella, F. W. 386, 404
Perry, H. 11, 14
Pertile, P. 116, 129, 138
Pessin, M. S. 397, 406
Peters, G. F. J. 143–144, 159
Peters, G. J. 145, 160
Peters, K. G. 400, 407
Peters, W. H. M. 21, 29
Petersen, P. A. 86, 96
Petrelli, N. J. 144, 160
Petroff, O. A. C. 260, 264
Petsko, G. A. 168–169, 179
Pheasant, A. E. 375, 380
Pianetti, P. 259, 264
Piantadose, C. 386, 404
Pignede, G. 338, 347
Pike, M. C. 133, 139
Pinedo, H. M. 22, 29, 143–145, 159–160
Pink, J. J. 168, 179
Pinna, L. A. 386, 403
Piper, J. R. 171, 179
Piulenas, I. 319, 323
Placidi, M. 22, 29
Planta, R. J. 360, 363
Plantavid, M. 115, 132, 136
Plante, J. 4, 11–13
Plese, P. C. 152, 161
Poenie, N. P. 391, 407
Pohland, R. C. 367, 380
Poll, W. 319, 323
Pomije, C. 220, 226
Porquet, D. 91, 94, 97
Porter, J. 201, 222
Povey, S. 85–86, 96
Powis, G. 385–386, 402, 404
Pozzan, T. 187–189, 198
Prabhu, R. 153, 162
Prajda, N. 33–36, 39, 45, 47–48, 54–55
Preisegger, K.-H. 353, 362
Prelli, F. C. 320, 323
Prendergast, N. J. 153, 162
Prentki, M. 207–208, 210–212, 220, 223
Previati, M. 110, 114
Price, G. M. 75, 82
Price, L. S. 130, 138–139
Price-Jones, J. M. J. 336, 338, 346
Prichard, J. W. 260, 264
Priest, D. G. 367, 376, 380
Priestman, D. 220, 226
Princen, H. M. G. 360, 363
Printz, R. 199, 205, 222
Prior, A. M. 246, 262
Prip-Buus, C. 203–207, 210, 223
Profy, J. R. 336, 346
Prokipcak, R. D. 15, 162
Prosser, S. 132, 139
Prostko, C. 211, 224
Proud, C. G. 192–194, 198
Przybyla, A. E. 168, 179
Pujol, A. 209, 224
Purchio, A. F. 288–289, 302
Putney, J. W. 58, 70
Putney Jr., J. W. 246–247, 250, 254–255, 262–263
Putney, S. D. 336, 346
Puzenat, N. 214–215, 217–218, 225–226

Qin, X.-Q. 287, 299, 302–303
Qiu, R.-G. 131, 133, 139

Quaas, R. 68, 71
Quians, Y. 386, 403

Raben, D. M. 397, 406
Rabenti, D. M. 397, 406
Rabes, H. M. 110, 113
Radin, N. S. 272, 280
Radulovic, S. 386, 402
Ragan, C. I. 246, 262
Ragan, I. 246, 262
Ragan, I. C. 246, 262
Rahman, K. 357, 363
Rahmani, R. 22, 29
Rakkit, S. 4, 11–13
Rana, R. S. 115–116, 135, 245, 262
Rance, D. 86, 96
Randall, R. J. 36, 55, 88, 96, 309, 323
Randazzo, P. A. 129, 138
Randle, P. J. 184–185, 196–197
Rangan, L. A. 397, 406
Ranor, R. L. 387, 405
Rao, L. 292, 297, 302
Rao, L. G. 145, 160
Rao, P. P. R. 375, 380
Rapp, U. R. 387, 405
Ratnam, M. 365–366, 371, 379
Ray, M. S. 367, 379
Raymondjean, M. 214–218, 225–226
Read, M. 216, 225
Real, F. X. 386, 402
Reardon, M. A. 36, 49, 51, 55
Reddy, K. K. 115, 135
Redford, K. S. 360, 363
Redmond, C. 144, 160
Reed, J. C. 298, 303
Reed, L. J. 183–184, 195–196, 196
Reeve, H. L. 246, 263
Regenass, U. 386, 403
Rehder, D. 68, 71
Rehkap, D. 69, 71
Reichman, M. 229–230, 240–243,
Reid, D. 187, 197
Reid, G. G. 246, 262
Reizenstein, P. 375, 380
Ren, Z. 386, 403
Renesto, P. 333, 346
Renold, A. 199, 205, 222
Resing, K. 22, 29
Reutter, W. 387, 405
Rey, D. A. 4, 14
Rey, I. 386, 403
Reyno, L. M. 386, 402
Rhee, S. 59, 70
Rhee, S. G. 101–102, 112–113, 115, 133, 136, 400, 406–407
Ricanati, E. S. 320, 323
Ricciardone, M. D. 153, 162
Richards, D. A. 185, 197
Richards, R. 10, 14
Richelson, E. 250, 263
Ridley, A. J. 130, 138–139
Riebow, J. 386, 404
Rientjes, J. Mj. 360, 363
Ringe, D. 168–169, 179
Rinzel, S. M. 367, 379
Riordan, J. R. 26, 29
Risser, R. 336, 346
Rittenhouse, S. E. 131, 139
Ritter, J. K. 86, 96
Riu, E. 209, 224
Rizzo, M. T. 33–36, 39, 54
Rizzuto, R. 187–189, 198
Robb-Gaspers, L. D. 187–188, 198
Robbins, K. C. 400, 406
Robbins, P. D. 283, 301
Roberts, A. B. 291, 302
Roberts, M. 59–60, 62, 66, 69–71
Roberts, M. F. 57
Robertson, J. B. 400, 406
Robins, D. J. 386, 403
Robins, E. 309, 323
Robinson Jr., W. E. 338, 347
Roche, E. 207–208, 210–212, 220, 223
Roche, S. 123, 138
Rockette, H. 144, 160
Rode, W. 165, 178
Rodrigues, M. 386, 403
Roeder, R. 216–217, 225
Roelofsen, B. 353, 362
Roeske, W. R. 246, 263
Romaniuk, P. J. 152, 161
Romond, E. H. 144, 160
Roninson, I. B. 352, 362
Rosebrough, N. J. 36, 55, 88, 96, 309, 323
Rosel, J. 386, 403
Rosenberg, I. H. 370, 380
Ross, J. 155, 162
Ross, J. F. 365–366, 371, 379
Ross, L. I. 336, 346
Ross, M. 210, 224
Ross, R. A. 246, 262
Rossana, C. 145, 160, 165, 178
Roth, J. A. 386, 403
Rothberg, K. G. 365, 378
Rott, R. 325–326, 328, 331, 344–345
Rouault, T. A. 153–154, 162
Rouser, G. 59, 70
Rousseau, G. 220, 226
Rowan, S. 297–298, 303
Roy, C. C. 357, 363
Ruana, A. R. 34, 54
Rubalcaba, 153, 162

Rubbini, S. 33–34, 54, 103–107, 109, 113
Rubio, I. 123, 137
Ruderman, J. V. 4, 7, 10, 13
Ruegg, U. T. 250, 257, 264
Ruetz, S. 353, 362
Ruiz Ruano, A. 115–117, 119–120, 122, 125, 136
Ruiz-Larrea, F. 123, 137
Rusche, D. P. 336, 346
Russell, C. A. 171, 179
Russell, D. W. 360, 363
Russell, F. A. 4, 14
Rustum, Y. M. 165, 171, 178–179
Rutter, G. A. 183–186, 188–191, 194–195, 197–198
Rutter, W. J. 168, 179
Ryle, A. P. 333, 345
Ryu, S. 59, 70
Ryu, S. H. 102, 113, 400, 406

Sabatini, D. M. 123, 137
Sabbatini, P. 292, 297, 302
Sacchi, N. 355, 363
Saenger, W. 68, 71
Safa, A. R. 17, 19, 23, 27
Saffitz, E. 101, 112
Sager, R. 302
Saggerson, E. 200, 222
Saino, T. 269, 280
Saison Behmoaras, T. 386, 403
Saito, D. 268, 274, 280
Sakai, K. 326, 328, 335, 345
Sakai, T. 283, 301
Sakamoto, K. 203, 223
Sakata, Y. 143–144, 159
Salari, H. 387, 405
Saleh, A. M. 375, 380
Sallenave, J.-M. 333, 345
Sallese, M. 110, 113
Saltiel, A. R. 190, 198, 386, 403
Salvatore, M. 269, 280
Samarut, J. 286, 301
Sambrook, J. 165–166, 168, 178, 355, 363
Samet, J. 145, 160
Samuels, L. L. 367, 379
Sandeen, M. A. 386, 404
Sanders, J. M. 365, 378
Sanders, K. H. 18, 22, 27
Santi, D. V. 143, 152, 159, 161
Sanz, L. 387, 405
Sarre, T. F. 250, 259, 264, 387, 404
Sato, A. 4, 6–7, 10, 14, 307–308, 323
Savatier, P. 286, 301
Sawadago, M. 216–217, 225
Sawamura, M. 268, 274, 280
Scanlon, K. J. 165, 178, 386, 403
Schaap, D. 397, 406
Schally, A. V. 386, 402
Schaub, T. 18, 21–22, 28–29
Scheid, A. 325, 328, 344
Schellekens, J. M. M. 338, 347
Scheper, R. J. 20, 22, 28–29
Schimke, R. T. 172, 179
Schimmel, P. 152, 161
Schimmel, P. R. 152, 161
Schindler, K. 165
Schinkel, A. H. 352–353, 355–356, 360–363
Schlegel, R. 284, 301
Schlessinger, J. 123, 137
Schmid, K. 307, 323
Schmidt, L. J. 77, 83
Schmidt, W. F. 401, 407
Schmitz, J. C. 367, 376, 380
Schneider, U. 123, 137
Schnieders, E. A. 123, 137
Schoepp, D. 240, 243
Schornagel, J. H. 143, 159
Schrama, L. H. 115, 135
Schreglmann, R. 201, 222
Schreiber, S. L. 123–124, 137–138
Schrenk, D. 353, 362
Schroder, H. C. 7, 10, 14
Schu, P. V. 123, 137
Schubert, C. 385, 386, 404
Schulman, H. 400, 407
Schulte-Hermann, R. 288–289, 292, 297, 302
Schultz, R. M. 367–369, 376, 379–380
Schultz, T. F. 336, 338, 346
Schulz, A. 386, 404
Schulz, J. T. 115, 119, 136
Schulz, R. 246, 263
Schumacher, W. 398, 406
Schwart, A. 319, 323
Schwartz, F. W. 190, 198
Schwartz, H. L. 284, 301
Schwartz, M. A. 131, 139
Schwarz, J. K. 298–299, 303
Schweighar, S. 386, 402
Schweizer, M. 201, 222
Sebti, S. M. 386, 403
See, C. G. 86, 96
Seedorf, K. 123, 137
Seelig, S. 284, 301
Seemuller, U. 333, 346
Seewald, M. J. 386, 404
Segal, S. 155, 162, 165, 178
Seguin, E. B. 250, 260, 263–264
Seitz, M. B. 187–188, 198
Selhub, J. 370, 380
Sell, S. 353, 362

Selvakumaran, M. 298, 303
Seman, M. 338, 347
Semba, K. 167, 178
Semenkovich, C. 203, 223
Senafi, S. B. 85
Seno, T. 145, 160, 165, 178
Serra, M. 246, 263
Seto, J. T. 326, 328, 331, 345
Seyfert, S. 319, 323
Shackelford, K. A. 365, 367, 366, 369, 371, 379
Shah, S. V. 284, 301
Shahinian, A. H. 145, 160
Shan, B. 283, 299, 301, 303
Shane, B. 366, 368, 379–380
Shao, Z. 283, 301
Sharma, S. 288–289, 302
Shashidhar, M. 59, 62, 70
Shea, T. B. 246, 263
Shears, S. B. 246, 254–255, 262
Sheen, Y. Y. 86, 96
Shen, F. 33, 365–366, 379
Shen, T.-Y. 190, 198
Shenolikar, S. 289, 302
Sherley, J. L. 153, 162
Sherman, M. L. 75, 80, 83
Sherman, W. R. 229, 243, 246, 260, 262, 264
Sherrard, D. J. 307, 323
Shih, C. 365, 367–369, 376–377, 379–381
Shih, H. 215–218, 225
Shiio, Y. 283, 301
Shimeno, H. 272, 280
Shimizu, K. 145, 160, 165, 178
Shin, T. B. 123, 137
Shin-Hs, H. S. 397, 406
Shinozuka, K. 287, 302
Shirahama, T. 307, 323
Shitara, T. 386, 403
Shoji, J. F. 387, 405
Shoji, M. 387, 405
Shorr, R. 59, 70
Shute, J. K. 246, 262
Sidi, Y. 75, 83
Sidransky, D. 157, 163
Sies, H. 18–19, 28
Siest, G. 85, 96
Sikorska, M. 10, 14, 284, 301
Silva, A. 333, 345
Silverman, G. A. 172, 179
Silverman, H. S. 187–188, 197
Silverman, J. A. 353, 362
Simonsson, P. 250, 263
Simpson, A. W. M. 187–188, 198
Simpson, I. 199, 221
Simpson, R. U. 386, 401, 403, 407
Singhal, R. L. 33–36, 39, 43, 45, 47–48, 54
Sinibaldi, V. J. 386, 402
Sirito, M. 217, 225
Sirotnak, F. M. 367, 379
Sizeland, A. M. 279, 281
Sjin, R. T. T. 298, 303
Sjoberg, B.-M. 11, 14
Sjolin, L. 68, 71
Skinner, A. 307, 323
Sklar, L. A. 131, 139
Skolnick, P. 241, 244
Skolnik, E. Y. 123, 137
Sladeczek, F. 240, 243
Slaughter, C. A. 360, 363
Sledge, Jr. G. W. 33–36, 43, 47–48, 54
Slomiany, B. L. 365, 379
Smit, J. J. M. 352–353, 355–356, 360–363
Smit, K. 145, 160
Smith, A. J. 17–18, 23, 27, 352–353, 361–362
Smith, C. D. 115, 131, 136
Smith, D. H. 337, 346
Smith, J. J. M. 17–18, 23, 27
Smith, J. L. 387, 405
Smith, J. M. 79, 84
Smith, M. R. 400, 406
Smith, S. 201, 222
Snoeck, G. T. 110, 114
Snowden, R. T. 288, 302
Snyder, S. H. 123, 137
Soffir, R. 352, 362
Sogame, Y. 18, 28
Sollot, S. J. 187–188, 197
Sols, A. 211, 224
Soltoff, S. 385, 402
Soltys, C. 62, 71
Someno, T. 269, 280
Sorrell, S. 353, 362
Sotos, G. A. 143–144, 159
Sozeri, O. 387, 405
Spahr, P.-F. 150, 161
Sparks, K. E. 17, 27
Spears, C. P. 145, 160
Spears, P. C. 145, 160
Spector, T. 9–10, 14
Spencer, D. D. 260, 264
Spengler, B. A. 246, 262
Spertini, F. 319, 323
Speth, V. 386, 404
Spiegel, A. M. 396, 405
Spriggs, D. R. 75, 80, 83
Spurr, C. L. 144, 160
Spychala, J. 75, 78, 83
Sridhara, R. 386, 402
Srimatkandada, S. 170, 179

Srivastava, S. K. 35, 54
St. Pierre, M. 18, 28, 351, 361
Stabel, S. 387, 404–405
Stac, J. 39, 41, 55
Stack, J. H. 123, 137–138
Standard, N. M. 4, 7, 10, 13
Starkhammer, H. 143, 159
Starzyk, R. M. 152, 161
Stathopulos, I. 201, 222
Stec, J. 133, 140
Steeper, J. R. 4, 14
Steer, C. J. 283, 291, 294, 296, 302
Stehman, F. B. 35, 55
Stein, C. A. 287, 302, 386, 402
Stein, R. B. 11, 14
Steinberg, S. M. 144–145, 160, 165, 178
Steitz, J. A. 147, 155, 161
Stekar, J. 385–386, 398, 404, 406
Stephens, L. 131, 139
Stephens, L. R. 116, 124, 138
Stephens, P. E. 336, 338, 346
Sterk, P. J. 333, 345
Stern, M. D. 187–188, 197
Steuart, C. E. 4, 14
Stevens, R. L. 309, 323
Stevenson, I. 123, 137
Stewart, A. J. 17, 18, 23, 27
Stewart, M. A. 229, 243
Stijnen, T. 333, 345
Stokoe, D. 131, 139
Stolz, A. 361, 363
Stone, D. 187, 197
Stone, W. J. 320, 323
Stonehuerner, J. G. 9–10, 14
Stoops, J. 201, 222
Stoppelli, M. P. 269, 280
Stornaiuolo, A. 110, 113
Stowers, L. 130, 139
Stoyanov, B. 123, 137
Stoyanova, S. 123, 137
Stravitz, R. T. 361, 363
Strocchi, E. 22, 29
Stroud, R. M. 143, 159
Stroup, D. 360, 363
Stubbs Jr., E. B. 260, 264
Stubbs, M. 36, 45, 55
Stumpo, D. 211, 224
Stuppia, L. 110, 113
Sturgill, T. W. 387, 405
Subasinghe, C. 287, 302
Subramaniam, M. 77, 83
Sudo, Y. 219, 226
Sudol, M. 172, 179
Sugar, J. 102, 104, 112
Sugarbaker, P. H. 171, 179
Sugden, M. C. 184, 196
Sugimura, T. 268, 274, 280
Suh, H. W. 102, 113
Suh, P. 59, 70
Suh, P. G. 102, 113, 400, 406
Suimada, Y. 143–144, 159
Sukegawa, J. 167, 178
Sul, H. 201, 203, 222–223
Sultan, C. 115, 136
Sultzman, L. 400, 406
Sun, Z.-M. 288, 302
Sundell, S. 69, 71
Sundler, R. 34, 54
Sutherland, C. M. 144, 160
Sutherland, L. 85, 88, 96
Sutton, C. 336, 338, 346
Sutton, G. P. 35, 55
Suzuki, K. 75, 80, 83–84
Suzuki, M. 307, 323
Suzuki, Y. 320, 324
Svensson, L. 59, 65, 70
Swain, S. M. 144–145, 160
Swain, S. M. 165, 178
Sweetman, B. 19, 21–22, 28
Swell, L. 356, 363
Sylvia, V. 39, 41, 55, 133, 140
Symons, M. 131, 139
Symons, M. H. 133, 139
Szekely, L. 286, 301
Szelenyi, J. 102, 104, 112
Szepeshazi, K. 386, 402
Szoke, B. 386, 402
Szondy, S. 36, 55

T'Ang, A. 297–298, 302
Tagger, A. Y. 10, 14
Taguchi, T. 59, 70, 143–144, 159
Taheri, M. R. 75, 82
Taillon-Miller, P. 172, 179
Tainsky, M. 386,403
Takahashi, Y. 279, 281
Takanashi, S. 22, 29
Takechi, T. 152, 155, 162, 165, 178
Takeda, E. 39, 55
Takegawa, K. 123, 137
Takeishi, K. 145, 160, 165, 178
Takemura, H. 247, 250, 263
Takenawa, T. 115, 129, 132–133, 135–136, 140
Takeuchi, T. 272, 278, 281
Takeyama, H. 75, 83
Takikawa, H. 18, 28
Takimoto, C. H. 146, 150–151, 153, 161–162
Tamiya-Koizumi, K. 133, 140
Tan, C. 57
Tanaka, T. 201, 211, 222, 224

Tang, G. 190, 198
Tanuguchi, N. 322, 324
Tashiro, M. 326, 328, 330–331, 335, 345
Tavare, J. M. 188–189, 192, 198
Taylor, C. 201, 223
Taylor, E. C. 367, 368, 379, 380
Taylor, G. A. 367, 375, 379–380
Taylor, J. M. 386, 401, 403, 407
Teeter, L. D. 353, 362
Tempst, P. 123, 137
Tendrich, G. 333, 345
Tephly, T. R. 85–86, 96
Teriele, H. P. J. 352, 362
Terrat, J. G. 320, 323
Tersmette, M. 338, 347
Tertoolen, L. G. J. 133, 139
Testoni, F. 22, 29
Thatcher, G. 60, 71
Thelander, L. 4, 7–14
Thelander, M. 4, 7–10, 14
Theler, J. M. 188, 198
Thiebaut, F. 352, 361
Thomas, A. P. 184–188, 190–191, 197–198
Thomas, G. M. H. 129, 132, 138–139
Thomas, P. 211, 224
Thomas, R. 386, 402
Thomas, S. 35, 55
Thompson, A. 123, 137
Thompson, C. B. 75, 80, 83, 289, 302
Thompson, K. 214, 217–218, 225
Thompson, R. C. 333, 346
Thomson, S. 336, 338, 346
Thorburn, A. M. 289, 302
Thorens, B. 199, 221
Thorgeirsson, S. S. 353, 362
Thorner, J. 123, 128, 137–138
Thuong, N. T. 386, 403
Tiedeman, A. A. 79, 84
Tiefenbacher, R. 288–289, 302
Timmermans-Hereijgers, J. L. P. M. 353, 362
Tkaczuk, K. H. 386, 402
Tlsty, T. D. 292, 302
Tobita, K. 326, 328, 331, 345
Tocque, B. 386, 403
Toh-e, A. 128, 138
Toker, A. 115, 135
Tolias, K. M. 130–131, 139
Tone, T. 386,403
Totty, N. F. 123–124, 137–138
Toullec, D. 259, 264
Towatari, T. 325
Towle, H. 214–218, 225–226
Toyoshima, K. 167, 178
Tran, D. 115, 136
Tran, H. M. 86, 96
Traxinger, R. 210, 224
Traxler, P. 386, 403
Traynor-Kaplan, A. 131, 139
Traynor-Kaplan, A. E. 131, 139
Tremp, G. 214, 225
Trepel, J. 143, 146, 159
Tricot, G. J. 75, 83
Trinks,U. 386, 403
Tron, P. 215–216, 225
Trowsdale, J. 365, 379
Trullas, R. 241, 244
Truong, O. 122–124, 137–138
Tsien, R. Y. 391, 396, 405, 407
Tsujikawa, M. 201, 223
Tsuruo, T. 352, 361
Tuchweber, B. 357, 363
Tuerk, C. 150, 161
Turner, J. 59, 70
Twentyman, P. R. 22, 29
Twisk, J. 360, 363
Tytgat, G. 94, 97
Tytgat, G. N. J. 360, 363

Uberall, F. 385–387, 389–390, 392–393, 396, 400, 403–405
Ueda, N. 284, 301
Uhlenbeck, O. C. 152, 161
Ulloa, N. 353, 362
Ullrich, A. 400, 406
Ullrich, S. J. 155, 162
Ulrich, W.-R. 18, 22, 27
Umezawa, H. 268–269, 274, 280
Umezawa, K. 267–268, 270–274, 276, 278–281
Unger, C. 386, 387, 404, 405
Unger, M. 386, 402
Unitt, J. F. 187, 197
Uno, I. 128, 138
Urumow, T. 115, 131, 135, 139
Uzan, M. 320, 323

Vacca, C. V. 320, 323
Vacchio, S. D. 269, 280
Vagelos, P. 201, 222
Vahidi, H. 387, 405
Valdimarsson, G. 19, 28
Valera, A. 209, 224
Valius, M. 400, 406
Vallet, V. 208, 224
Valmori, A. 101, 112
Van Bergen en Henegouwen, P. M. P. 101, 110, 112, 115, 132–133, 136
Van Blitterswijk, W. J. 353, 362
Van Cutsem, E. 143, 159

Van de Vijver, M. 87, 96
Van de Werve, G. 212, 225
Van Deemter, L. 352, 356, 362
Van den Bergh Weerman, M. A. 360, 363
Van der Lugt, N. M. T. 352, 356, 362
Van der Valk, M. A. 352, 356, 360, 362–363
Van der Steen, Ad. A. B. 21, 29
Van Der Wilt, C. L. 145, 160
Van Dongen, C. J. 115, 135
Van Dyke, M. 217, 225
Van Ettan, R. 69, 71
Van Mourik, J. H. G. 110, 114
Van Nieuwkerk, C. 351
Van Nieuwkerk, C. M. J. 360, 363
Van Roon, M. A. 352, 356, 362
Van Schaftingen, E. 208, 210, 213, 223–224
Van Tellingen, O. 17, 22, 27
Van Wijland, M. 360, 363
Van Wijland, M. J. A. 351–352, 355–356, 362
Van-Blitterswijk, W. J. 397, 406
Vandeemter, L. 352, 361–362
Vandercammen, A. 208, 213, 224
Vanhaesebroeck, B. 123, 137
Vantellingen, O. 352, 362
Vanzel, T. 320, 323
Vaughan, P. F. T. 246, 263
Vaulont, S. 212, 214, 217–218, 224–226
Vedejs, E. 386, 403
Verkleij, A. J. 101, 110, 112, 115, 132–133, 136
Verkruisen, R. P. 360, 363
Versantvoort, C. H. M. 17–18, 22–23, 27, 29
Vicendo, P. 123, 138
Vincent, J.-D. 255, 264
Vintermyr, O. K. 289, 302
Visa, J. 209, 224
Vlahcevic, Z. R. 360–361, 363
Vlahos, C. J. 386, 404
Voegeli, R. 398, 406
Voeller, D. 146, 150–151, 153, 161–162
Voeller, D. M. 152, 155, 162, 165, 178
Vogelstein, B. 155, 157, 162–163
Vogler, W. R. 387, 405
Vogt, A. 386, 403
Volinia, S. 123, 137
Vollmer, K. 387, 405
Volpe, J. 201, 222
Volwerk, J. 59, 62, 70
Vonk, R. J. 21, 29
Vos, G. V. 229–230, 241–243
Vu, T. K. H. 396, 405
Wagenaar, E. 352, 356, 361–362
Wagman, A. 60, 66, 71
Wagner, A. 292, 297, 302
Wagner, C. 386, 403
Wagner, P. 123, 137
Wahrer, D. C. R. 22, 29
Wajda, I. 255, 264
Wakelam, M. J. 387, 405
Wakil, S. 201, 222
Wakui, A. 143–144, 159
Walker, C. 110, 113
Walker, P. R. 10, 14, 284, 301
Walker, S. 217, 225
Wallin, B. K. 87, 96
Wallner, O. 333, 345
Walter, S. 365, 379
Walters, J. 375, 380
Walters, R. 131, 139
Waltner, C. 153, 162
Walts, A. E. 320, 324
Wang, C. Y. 110, 113
Wang, J. Y. J. 283, 301
Wang, S. J. 168, 179
Wang, X. 365–366, 379
Wang, X.-F. 298, 303
Wang, Y.-C. J. 284, 301
Waserman, 75, 83
Washtien, W. L. 143, 145, 159
Waterfield, M. D. 123–124, 137–138
Watling, K. J. 246, 262
Watson, M. 246, 263
Wauters, J. P. 319, 323
Waxman, D. J. 94, 97
Waymack, P. 69, 71
Weber, A. 357, 363
Weber, G. 33–37, 39, 43, 45, 47–49, 54–55, 75–76, 80, 82–84, 102–104, 107, 109, 112–113, 242, 244, 260, 264
Weber, K. 7, 10, 14
Wedge, S. R. 367, 375, 380
Weening, J. J. 333, 345
Wehland, J. 7, 10, 14
Wei, X. 210, 224
Weinberg, R. A. 283, 301
Weinert, T. A. 123, 137
Weinhold, K. J. 338, 346
Weinstein, I. B. 387, 405
Weiss, R. A. 325, 336, 345–346
Weitman, S. D. 365, 378
Welch, P. J. 283, 301
Welsh, G. I. 192–194, 198
Wels,W. 386, 403
Welt, S. 386, 402
Weltzien, H. U. 386, 404
Wennstrom, S. 131, 139
Werner, A. 336, 338, 346

Wessendorf, M. W. 291, 294, 296, 302
Westerman, J. 115, 118, 135
Westin, E. H. 365, 379
Wetzker, R. 123, 137
Wheaton, V. I. 396, 405
Wheeler, H. O. 356, 363
White, A. E. 292, 302
White, E. 283, 292, 297, 301–302
White, M. F. 192, 198
White, S. I. 272, 276, 280–281
Whitehead, P. W. 4, 11–13
Whitfield, J. F. 10, 14
Whithman, E. M. 246, 255, 263
Whitworth, P. 229, 243
Whyte, W. 170, 179
Wickerham, D. L. 14, 160
Wiedenmann, K. 333, 346
Wieder, T. 387, 405
Wieland, O. H. 115, 131, 135, 139, 190, 198
Wigzell, H. 338, 346
Will, C. L. 171, 179
Willems, L. N. A. 333, 345
Williams, B. O. 298, 303
Williams, L. T. 400, 407
Williams, M. B. 229, 243
Williams, S. S. 46, 55
Williams-Ahlf, B. 201, 222
Williamson, J. R. 231, 243
Willingham, M. C. 352, 361
Willis, S. A. 365, 378
Wilson, D. B. 34, 54, 250, 263
Wilson, E. 400, 407
Wilson, G. M. 17, 27
Wilson, M. G. 309, 323
Wiman, K. G. 286, 301
Winkler, P. M. 165
Winter, R. B. 150, 161
Wintersberger, E. 153, 162
Wirtz, K. W. A. 110, 114–116, 118, 120, 135–136, 353, 362
Wlodawer, A. 68, 71
Wolkoff, A. W. 26, 29
Wollheim, C. 207, 223
Wollheim, C. B. 188, 198
Wolmark, N. 144, 160
Wong, K. 123, 138
Wong, Y. 59–60, 65–66, 70–71
Wooster, R. 85, 96
Workman, P. 385–386, 402–403
Worzalla, J. 365
Worzalla, J. F. 369, 376, 380, 381
Wright, C. S. 333, 345
Wright, J. A. 10, 14
Wright, T. M. 397, 406
Wu, J. 291, 302
Wu, J. C. 76, 79, 82–83
Wu, X. 298, 300, 303
Wu, Y. 57

Xiao, D. 59, 70
Xu, R. 291, 294, 296, 302
Xu, X. 130, 138

Yagi, G. 250, 263
Yagisawa, H. 128, 138
Yamada, N. 322, 324
Yamada, T. 307, 323
Yamaguchi, N. 283, 3001
Yamaji, Y. 75–76, 83
Yamakawa, M. 328, 345
Yamamoto, A. 124, 126, 128, 138
Yamamoto, T. 167, 178, 276, 279, 281, 283, 301
Yamamura, H. I. 246, 263
Yamanaka, G. 11, 14
Yamanashi, Y. 167, 178
Yan, C. 201, 222
Yan, J. 195, 198
Yang, H. 33, 35–36, 39, 43, 48, 55
Yarden, Y. 400, 406
Yarranton, G. T. 336, 346
Yates, J. L. 150, 161
Yeaman, S. J. 183–184, 196
Yeatman, M. T. 86, 96
Yee, D. 246, 263
Yeh, G. C. 145, 160
Yeh, S. D. 386, 402
Yeh, Y. A. 33–36, 39, 43, 45, 48, 54–55
Yin, H. L. 130, 138
Yin, M.-B. 171, 179
Yoko-o, T. 128, 138
Yokogoshi, Y. 326, 328, 331, 345
Yonezawa, K. 123, 138
Yoon, H. S. 115, 135
York, J. D. 101, 110, 112, 133, 140
Yoshida, S. 123–124, 126, 128, 133, 137–138, 140
Yoshino, M. 143–144, 159
Youdale, T. 10, 14
Youn, J. 212, 225
Youn, M. 212, 225
Yousef, I. M. 357, 363
Yu, A. L. 75, 83
Yu, H. 124, 138
Yu, J. 75, 83

Zalcberg, J. 143, 159
Zalkow, L. 386, 404

Zaman, G. J. R. 17–18, 20, 22–23, 27–28, 352, 361
Zeitman, B. B. 309, 323
Zeller, K.-P. 22, 29
Zhan, Q. 157, 163
Zhang, J. 131, 139
Zhang, J. T. 355, 362
Zhang, X. 192, 198
Zhang, Z.-G. 165, 178
Zhao, Y.-H. 172, 179
Zheng, B. 387, 405
Zheng, L. 17, 19, 23, 27
Zhou, C. 57, 60, 62, 71
Zhou, X. J. 22, 29
Zhu, G. 386, 403
Zimmerman, A. 75
Zimmermann, A. G. 78, 83
Zini, N. 101, 112
Zinn, S. 145–148, 150, 160–161, 165, 178
Zuhowski, E. G. 386, 402
Zukowski, K. 110, 113

SUBJECT INDEX

ACC *see* acetyl-CoA carboxylase
acetyl choline (ACh), lithium effects on phosphoinositide signalling in human neuroblastoma cells 248–53
acetyl-CoA:CoA ratio, kinase activity 183–4, 190
acetyl-CoA carboxylase (ACC)
  expression
    glucose metabolism 202–3, 207–9, 220–1
    glutamine 210
    mannose 212
  glucose transport 190
  lipogenesis pathway 199–203
  mRNA 202–3
  PDH regulation 183–98
  wortmannin 194
acid phosphatase levels, hemodialysis 318–22
acquired immune deficiency syndrome (AIDS)
  see also human immunodeficiency virus
  HIV proteolytic activation 325–8, 336–44
actinomycin D, lipogenesis activity 202
adhesion
  animal virus proteolytic activation 325–44
  conophylline inhibition 279
adipocytes
  lipogenic enzyme expression regulation by glucose 199–226
  permeabilized by electroporation, PDH regulation 194–5
ADP, ATP demand 186
ADP-ribosylation factor (ARF), phosphatidylinositol[4,5]bisphosphate 129
adrenal medulla, PIP5-kinases 115
adrenaline, PDH activation 187
β-adrenergic agonist, activating effect 184
adriamycin, TS overexpression 145
advanced glycation end (AGE) products, hemodialysis-associated amyloidosis 322
aequorin photoprotein 188
AGE *see* advanced glycation end products
agonist-induced PKC stimulation, phospholipid analogues inhibition 395–7
AH7974 rat hepatoma cells, leupeptin 268–9
albumin
  AGE modified 322
  Alb I/Alb II ratio 307–22
  amyloid deposition 307–17
alcohols, bilirubin UGT 86
aldolase B (EC 4.1.2.13) 220
aliphatic alcohols, bilirubin UGT 86
alkylphosphocholines, antitumour 386
alkylphospholipids, mitogenic signal transduction 385–402
alveolar type II cells, pneumotropic animal virus activation 335
amino acid sequencing
  rTSα/rTSβ carboxy regions 168–70
  tryptase Clara cleavage products 331
  V3 loop peptides cleavage products 340–2
AMPA
  channels, IP_3 formation in mouse/rat cerebral cortex 240
  receptors, inositol-1,4,5-trisphosphate lithium-stimulated accumulation in monkey brain 233
amyloid deposition, hemodialysis-associated 307–22
animal enveloped viruses, proteolytic activation 325–44
anthracyclines 17
anthraquinones, bilirubin UGT 86
anti-epileptic drugs, valproate, glutamate release in mouse cerebral cortex slices 238–42
anti-tryptase Clara antibody, pneumotropic virus infection 331–333
antibacterials, metastasis 267–81
antibodies, anti-tryptase Clara 332
anticancer agents
  see also antitumour agents
  Friend cells nuclear PLC β_1 as target 102–4
  5-FU 143–5, 148
  microorganism/plant-derived 267–81
  nuclear inositol lipid cycle 102
  tiazofurin 102–4
antidepressants, lithium 229–43, 245–60

antifolates
  Lometrexol 365–81
  Tomudex 143
antileukoprotease (human), tryptase Clara inhibition 333
antiporters, sodium/hydrogen 396
antisense
  oligonucleotides
    IMPDH gene expression 77, 81
    retinoblastoma gene
      expression 292
      transfection 287
  recombinant thymidylate synthase 165–78
antitumour agents
  see also anticancer agents
  5-fluorouracil 143–5, 148
  hexadecylphosphocholine 386
  Lometrexol 365–81
  microorganism/plant-derived 267–81
  multidrug resistance protein 17, 21, 22
  phospholipid analogues 385–402
  phospholipids 385–402
apoptosis, retinoblastoma gene 283–303
arachidonic acid, Rho inducing 133
aromatic carboxylic acids, bilirubin UGT 86
astrocytoma cells, inositol uptake 241
ATCC CCL 17 (KB cells), rTSα transfection 168
ATP
  ADP 183–4, 186, 190
  Ca^{2+} 186–7
  lipogenesis pathway 199–200, 211
  NADH 186
  PDH regulation 188, 190
ATP-citrate lyase
  glucose effect 220
  lipogenesis activity 202
  phosphorylation 194
ATP-dependent transport
  glucuronate conjugates 18
  glutathione disulfide 20–1
  LTC_4 18, 22
  LTD_4 22
  MRP 17–18, 20–2, 26
  plasma membrane vesicles 19
atropine
  inositol-1,4,5-trisphosphate lithium-stimulated accumulation in monkey brain 231–2
  lithium effects on phosphoinositide signalling in human neuroblastoma cells 253–5
azaserine, L-pyruvate kinase (L-PK) gene 210

B16 melanoma, Lometrexol 368, 371–2
B16/F10 cells
  baicalein antimetastatic activity 275
  conophylline metastasis inhibition 279
  epi-CPL inhibition 273–4
  mannostatin A antimetastatic activity 276
Bacillus cereus 59
Bacillus subtilis 59, 79
Bacillus thuringiensis 59
bacterial proteases, mucous protease 335
baculovirus-infected insect cells, recombinant gp120 structure 338
baicalein
  antimetastatic activity 275
  structure 272
'BARBIE BOX' sequence, human bilirubin UGT 91, 94–5
barbiturates, bilirubin UGT gene regulation 87–8, 91, 94–5
beta microglobulin, hemodialysis-associated amyloidosis 307, 320, 322
BHK cells, bilirubin UGT1*1 gene expression 93–4
bile salts
  biliary phospholipid secretion relationship 356–60
  mdr2 gene regulatory role 351–61
biliary lipid secretion, *mdr1a/mdr2* gene 352–7
bilirubin UDP-glucuronosyltransferase (bilirubin UGT, EC. 2.4.1.17) 85–95
binding, tryptase TL2 to CD4 337
bombesin
  hexadecylphosphocholine inhibition of calcium release 399
  IP_3 formation 394
bone marrow
  enzyme half lives 47–8
  IP_3 concentration 46–7
  tiazofurin 48
Boyden chamber assays 272–3, 278, 279
brain, phosphatidylinositol-4-phosphate 5-kinases 115, 127
breast cancer, thymidylate synthase 144–5
bromodeoxyuridine (BrdU), cell cycle-related expression 292
bronchial epithelium, tryptase Clara-mediated virus activation 328–36

C3H mice, folate receptors/FPGS/Lometrexol 367–78
c-myc
  cell cycle-related expression 292–7
  GIRE oncogene 216

mRNA
thymidylate synthase 165
translation 155, 157
c-yes
mRNA
Northern blot analysis 173
overexpression in FU-resistant cells 171–2
5′-CACGTG-3′ sequence, glucose response elements 221
calcium ions
ATP demand 186–7
bombesin-induced release, hexadecylphosphocholine inhibition 399
formation of Ins(1,4,5)P_3 240
insulin 194
lithium effects on phosphoinositide signalling in human neuroblastoma cells 255–6
mobilization, phospholipase enzymes 59, 69
PDH regulation 184, 185–90, 196
phosphatidylinositol 4-phosphate 5-kinase secretion regulation 128–30
phospholipid analogues activity 395
release from nonmitochondrial stores 245
tryptase Clara activation 328
calcium-dependent serine/threonine kinases, phospholipid analogues inhibition of mitogenic signalling 386–7
cAMP responsive element binding protein (CREB) 218
camptothecin analogues, Irinotecan (CPT-11) 143
canalicular membrane
function 351
MDR2 P-glycoprotein 352
MRP-mediated transport 18–27
phosphatidylcholine translocation 353–4
CAPD *see* continuous ambulatory peritoneal dialysis
carbetapentane
glutamate release/inositol-1,4,5-trisphosphate accumulation in mouse cerebral cortex slices 236–9
lithium-induced IP_3 release 242
carbohydrate response element (ChoRE) 214
carbohydrates
control of metabolism 183–98
lipogenic pathway 199–200
Spot 14 gene 216
tumor cell surface 271–5
carboxylic acids, bilirubin UGT 86
(±)-3-(2-carboxypiperazin-4-yl)-propyl-1-phosphoric acid (CPP)
effects of receptor antagonists on lithium-stimulated accumulation of Ins(1,4,5)P_3 231–3
glutamate release/inositol-1,4,5-trisphosphate accumulation in mouse cerebral cortex slices 236–7, 238
carcinogenesis
IMPDH gene expression 75–6, 81, 82
ovarian 35–6
P-glycoprotein expression in liver 353
carpal tunnel syndrome (CTS), hemodialysis-associated 307–22
castanospermine, antimetastatic activity 272
CAT *see* chloramphenicol acetyltransferase
cathepsin G
mucous protease inhibitor activity 333
V3 peptides inhibition 338
cathepsin L, hemodialysis 318–22
CD4+ lymphocytes, HIV-1 membrane fusion 336
CD4 receptors
HIV-1 gp120 envelope glycoprotein binding 325, 336, 337
tryptase TL2 V3 loop interaction 343
cell cycle, retinoblastoma gene 283–303
cell membranes
animal viruses proteolytic activation 325–44
EGF ruffles 132
membrane ruffles, EGF 132
phospholipid analogues damage 398–9, 401
phospholipid biliary secretion 354
PIP kinase
purification/characterization 117–20
vesicular trafficking 128–30
transport, biliary phospholipid secretion 354
vesicular trafficking of phosphatidylinositol 4-phosphate 5-kinase 128–30
cell proliferation
human liver IMPDH expression 79, 81
IMPDH expression 75–6
mitogenic signalling 385–402
N1H3T3 fibroblasts, phospholipids effects on mitogenic signalling 389
retinoblastoma gene 283–303
thymidylate synthase 143–63, 165–80
cell-cell adhesion, conophylline inhibition 279
cellular proteases, animal virus activation 325–44

cellular signalling
  inositol lipid cycle 101–114
  phospholipid analogues
    inhibition 385–402
cerebral cortex
  lithium action mechanism 229–44
  mouse, glutamate release 237–42
CFTR *see* cystic fibrosis transmembrane conductance regulator
chemotherapy
  see also anticancer agents; antitumour agents
  phospholipid analogues inhibition of mitogenic signalling
    induction 385–402
  thymidylate synthase as target 143–63, 165–80
Chinese hamster ovary (CHO) cells, HIV-1 entry: tryptase TL2 325–8
chloramphenicol acetyltransferase (CAT)
  bilirubin UGT1*1 gene expression 93
  reporter gene
    constructs, IMPDH gene expression 77
    IMPDH type II gene-mediated transcription 79, 82
    transfection efficiency 287
chlorpheniramine,
  inositol-1,4,5-trisphosphate lithium-stimulated accumulation in monkey brain 231–2
cholate, murine *mdr2* expression 357–9
cholesterol
  glucose signal transmission 218
  homoeostasis, canalicular membrane 351–2
  secretion relationship with bile salts 356–7
cholinergic agents, inhibitory effects of lithium on Ins(1,4,5)P_3 accumulation 240–1
ChoRE *see* carbohydrate response element
chromosome mapping
  human liver bilirubin UGT 85–6
  PLC β_1 rat gene 109–10
chymase, mucous protease inhibitor activity 333
chymostatin, antimetastatic activity 269
α-chymotrypsin, mucous protease inhibitor 333–6
chymotryptic sites, HIV-1 III_B V3 loop peptide cleavage 342
ciliated cells, pneumotropic animal virus activation 335
cis elements, glucose responsiveness of lipogenic enzyme gene expression 214–16
Clara cells, tryptase Clara 325–44
cleavage *see* proteolytic cleavage
clinical trials, phospholipid analogues inhibition of mitogenic signalling 386
clofibrate, bilirubin UGT gene 89
cloning *see* DNA, cloning
cofactors, hexadecylphospho-[L]-serine growth-inhibitory effect 392
collagenases, leupeptin analogues inhibition 269–71
colorectal carcinoma
  5-fluorouracil 143–5, 148
  murine Lometrexol antifolate activity 368, 371–2
conformational changes
  albumin during hemodialysis 307–23, 325, 336
  V3 loop peptide cleavage 342
conjugate export pump, MRP-mediated 17–27
conophylline
  oncogene function inhibition 277
  Ras function inhibition 279
continuous ambulatory peritoneal dialysis (CAPD), plasma acid phosphatase 321
COS-7 monkey kidney fibroplast, bilirubin UGT1*1 gene expression 89–90, 93, 95
CPP *see* (±)-3-(2-carboxypiperazin-4-yl)-propyl-1-phosphoric acid
CPT-11 *see* Irinotecan
CREB *see* cAMP responsive element binding protein
Crigler-Najjar syndrome, bilirubin UGT1 mutations/defects 86
CTS *see* carpal tunnel syndrome
cyclin, retinoblastoma gene transcription 283
cycloheximide
  IP_3 concentration in bone marrow 46–7
  PLC nutritional control 51
cyclophellitol (CPL), structure 272
cysteine, MRP 20, 26
cystic fibrosis, ATP-binding cassette superfamily mislocalization 26
cystic fibrosis transmembrane conductance regulator (CFTR) 26
cytoplasmic pH, determination 390
cytosol
  calcium ions
    determination 391
    lithium-induced glutamate release 241
  cracked PC12 cells 128
cytosolic free calcium, thrombin mediated increase 395, 401

D20133 395, 398
D21266 395, 398

D21805 395, 398
DAG *see* diacylglycerol
dansyl-Leu-Arg-CHO, leupeptin analogue inhibition 269–71
daunomycin, transport into canalicular membrane 351
daunorubicin, P-glycoprotein pump 17
de novo purine synthesis
  folate cofactors 365
  folate-dependent enzymes 366–7
  IMPDH gene expression 75–84
6-deoxyglucose, ACC expression 208
2-deoxyglucose, lipogenic enzyme gene expression 211, 213, 221
2-deoxyglucose-6-phosphate, lipogenic enzyme expression 211–12, 213
deoxythymidylate, synthesis 165
dexamethasone, FAS mRNA 203
DHFR *see* dihydrofolate reductase
diabetic rats, glucose phosphorylating capacity 205
diacylglycerol (DAG)
  generation of 34–5
  mitogenic stimulation 387
  phospholipase C enzymes 57, 58, 69
  PI-specific PLC 395, 400
  PLC β_1 regulation 105, 110, 111
diacylphosphoramidocholine, TRNOE techniques 59
dialysis, amyloidosis 307–17
4′,6-diamino-2-phenylindole (DAPI), PLC β_1 regulation 110
6R-5,10-dideazatetrahydrofolate (Lometrexol), antitumour evaluation on low folate diet 367–81
dietary folate, folate receptor expression 365–81
digoxigenin, retinoblastoma gene transfection 288
dihexanoyl-sn-(3-N-benzylaminoglycero) phosphoramidocholine, solution conformation for PC-PLC 69
1,2-dihexanoyl-sn-(3-N-benzylaminoglycero) phosphoramidocholine 60, 66–7
dihydrofolate reductase (DHFR, EC 1.5.1.3)
  gene mRNA translation 150, 153
  pathway 366
  recombinant thymidylate synthase overexpression 170–1
dihydrolipoate acetyltransferase (E2) units 183
dihydrolipoate dehydrogenase units (E3) 183
dimethylsulfoxide (DMSO)
  lithium effects on phosphoinositide signalling in human neuroblastoma cells 246
  PLC β_1 down-regulation 101, 104, 111
dipeptidyl aminopeptidase levels, hemodialysis 319–22
dithiothreitol
  tryptase Clara activation 328
  V3 loop peptides cleavage products analysis 340
DNA
  cloning
    bilirubin UGT human liver gene 85–6, 88
    IMPDH
      type I gene 80
      type II gene 78–80
    phosphatidylinositol 4-phosphate 5-kinase 133
    phosphatidylinositol 4-phosphate 5-kinase II 122–5
  GIRE 216–18
  probes, recombinant thymidylate synthase preparation 167
  sequencing
    bilirubin UGT_1 gene constructs 88–91
    IMPDH gene 78–9
  synthesis
    guanine nucleotide influence 76
    rat hepatomas 39
    thymidylate synthase 143–59
  transfection
    bilirubin UGT gene expression 88, 90
    IMPDH gene expression 77
Drosophilia melanogaster, IMPDH sequencing 79
drug conjugate transport, multidrug resistance protein 17–29
drug resistance
  5-fluorouracil 144–5, 148
  recombinant thymidylate synthase expression 176
  trifluorothymidine 175
Dubin-Johnson syndrome, multidrug resistance protein 26–7
dUMP, thymidylate synthase 150–2, 176

E2F proteins
  apoptosis mediation 298–9
  cell cycle-related expression 292–3, 296–7
  regulation 300
  retinoblastoma gene transcription 283
E-cadherin, conophylline inhibition 279
EGF *see* epidermal growth factor
EGTA, calcium ion chelator 255–6
eIF-4E BP-1, phosphorylation 194

elastatinal, antimetastatic activity 269
electrophoresis *see* sodium dodecyl sulphate-polyacrylamide gel electrophoresis
endobiotics
  bilirubin UGT gene regulation 85
  multidrug resistance protein 18, 22
endogenous inhibitors, tryptase Clara 333–6
envelope fusion proteins
  HIV-1 gp120 336–44
  tryptase Clara cleavage 325–6, 328–36
  tryptase TL2 cleavage 336–44
enzyme inhibitors, metastasis inhibition 267–81
1,6-epi-cyclophellitol (epi-CPL), antimetastatic activity 271–5
epidermal growth factor (EGF)
  acetyl-CoA carboxylase activity 193
  insulin 191
  PDH activation 193
  receptor, phosphatidylinositol 4-phosphate 5-kinase activity 132–3
epipodophyllotoxins 17
epithelial cells, airway, tryptase Clara activity 333
erbstatin, tyrosine kinase inhibition 276–8
erythrocytes
  differentiation system, nuclear inositol lipid cycle 102–4
  hemodialysis patients 319
  PIP5Ks purification/characterization 115, 117–19
  polyphosphoinositide pools 116
Escherichia coli
  IMPDH sequencing 79
  lactose operon 219
  phosphatidylinositol 4-phosphate 5-kinase II 122–3, 125, 130
  proteins homology 169
ethinylestradiol, bilirubin UGT substrate specificity 86
etoposides
  multidrug resistance protein 19, 21–2
  P-glycoprotein pump 17
excitatory neurotransmitters, glutamate release in monkey/mouse brain 229–44
excretion, hepatocyte function 351–2
exocytosis, phosphatidylinositol 4-phosphate 5-kinase activity 129
expression
  hepatic *mdr2* P-glycoprotein 351–61
  retinoblastoma gene 283–303

F-type 6-phosphofructo-2-kinase (EC 2.7.1.105), glucose effect 220
FAB1 124–8
FAS *see* fatty acid synthase
fatty acid synthase (FAS)
  gene expression, glucose effect 201–6, 213–19, 220–1
  mannose 212
  mRNA 202–4, 206
  3-O-methyl glucose 205
  pentose phosphate pathway 213
FAZA cells, bilirubin UGT1*1 gene expression 87, 89–90, 92
ferritin, translational regulation 153–4
fetal bovine serum (FBS), retinoblastoma gene product 289–91
fibronectin, conophylline inhibition 279
flavones, bilirubin UGT substrate specificity 86
flippase, MDR2 P-glycoprotein in canalicular membrane of mouse hepatocyte 361
flow cytometry, retinoblastoma gene 288, 292
fluorescence *in situ* hybridization (FISH) 108–10
5-fluorouracil (5-FU)
  chemotherapeutic efficacy 143–5, 148, 171–2
  colorectal carcinoma 143, 144
  gene amplification 172
  thymidylate synthase mRNA 165, 171–2
folate receptors
  alpha, tumour marking 365
  beta, expression 365–6
  expression modulation by dietary folate 365–81
  folate utilizing enzymes 366
folate-dependent enzymes
  de novo purine synthesis 365–7
  novel 367
  thymidylate synthesis 366
folates
  deficient diet (LFD), Lometrexol antitumor activity 367–78
  5-FU resistance 145
folylpolyglutamate synthetase (FPGS, EC 6.3.2.17)
  de novo purine synthesis pathway 366
  Lometrexol antitumour evaluation 367–8, 372–3
  recombinant thymidylate synthase expression 171
  thymidylate synthesis pathway 366
FPGS *see* folylpolyglutamate synthetase
FRAP, rapamycin 191–2
Friend erythroleukemia cells 102–4, 111
fructose-1-6-bisphosphate, L-PK transcription 213

fructose-1-phosphate, L-PK
transcription 213
fructose-2-6-bisphosphatase (EC 3.1.3.46)
glucose effect 220
glycolysis 210
L-PK transcription 213
fructose-6-phosphate, lipogenic enzyme expression 211–14
5-FU *see* 5-fluorouracil
α-fucosidase, baicalein inhibition 275
fusion glycoproteins
HIV-1 gp120 V3 loop 336–44
tryptase Clara 343–4

G proteins, phosphatidylinositol 4-phosphate 5-kinase regulation 116, 130–2
β-galactosidase, baicalein inhibition 275
gamma interferon, thymidylate synthase induction 148
GARFT *see* glycinamide ribonucleotide formyltransferase
gastric cancer, thymidylate synthase 144
GC-3 colon cells, murine Lometrexol antifolate activity 368, 371–2
genes
amplification, FU resistant cells 172
expression
IMPDH 75–84
retinoblastoma gene 283–303
induction, *mdr2* gene 357–60
markers, bilirubin UGT1*1 gene complex 86
overexpression
P-glycoprotein 352
retinoblastoma gene product 297–8
regulation
bilirubin UGT_1 85–95
hepatic *mdr2* P-glycoprotein expression 351–61
IMPDH type I/II genes 75–84
structure
IMPDH typeI/II 78–81
UDP-glucuronosyltransferase 85–6
genomic cloning *see* DNA, cloning
GFAT, lipogenic enzyme expression 210
Gilbert syndrome, bilirubin UGT1*1 promoter mutation 92
GIRE *see* glucose response element
glucokinase
gene expression
ACC gene 207
diabetic rats 205
glucose-6-phosphate 213
lipogenic enzyme gene expression 221
mannoheptulose inhibition 208, 209
starved rat hepatocytes 208
glucosamine, hexosamine pathway 210
glucose
ACC mRNA 202–3
FAS mRNA 202–4
lipogenic enzyme expression 199–226
metabolism
ACC expression 207–9
FAS expression 206
L-PK expression 207–9
transport
actyl-CoA carboxylase activity 190
diabetic rats 205
glucose response element (GIRE) 214, 215–19
glucose transporters (GLUT) 199, 205
glucose-1-phosphate, signal metabolite 214
glucose-6-phosphatase, half-life 48
glucose-6-phosphate
FAS expression 205–6, 213
glucose effect 220
lipogenic enzyme expression, signal metabolite 213–14, 219, 221
medium glucose concentrations correlations 207
glucose-6-phosphate dehydrogenase, lipogenic enzyme expression 210–12
α-glucosidases, inhibition 272, 275
β-glucosidases, inhibition 272, 275
glucuronate conjugates 18, 21, 22
β-glucuronidase, baicalein inhibition 275
glucuronidation, bilirubin UGT gene regulation 85–95
GLUT *see* glucose transporters
glutamate, lithium-stimulated release via cerebral NMDA receptor activation 229–44
glutamine, ACC expression 210
glutathione disulfide (GSSG), multidrug resistance protein 20–1
glutathione *S*-conjugates, multidrug resistance protein 18, 20, 22, 26
glutathione S-transferase (GST) fusions, G proteins 130
glycinamide ribonucleotide formyltransferase (GARFT, EC 2.1.2.2), Lometrexol antitumour evaluation 367
glycine, effects of receptor antagonists on lithium-stimulated accumulation of $Ins(1,4,5)P_3$ 232
glycogen, lipogenic enzyme expression 210, 212
glycolipids, tumor cell surface 271–5
glycolytic metabolites, L-PK transcription 213

glycoproteins
  hepatic *mdr2* P-glycoprotein expression 351–61
  tumor cell surface 271–5
  viral post-translational proteolytic activation 325–44
glycosidase inhibitors, antimetastic activity 271–6
gp120 HIV-1 envelope glycoprotein
  CD4 receptor binding 325, 337, 342
  proteolytic cleavage 327–8, 339
  tryptase TL2 binding 327, 337
  V3 domain 336–44
growth factors
  IGF-1 105–6, 109–11
  oncogenic phospholid analogues inhibition 385–402
GSSG *see* glutathione disulfide
GTP-binding protein, phosphatidylinositol [4,5]bisphosphate 129, 130
GTPases, phosphatidylinositol 4-phosphate 5-kinase regulation 130
GTPγS, insulin-like effect 194, 196
guanine nucleotide exchange factor SOS 191
guanine nucleotides
  biosynthetic pathway 76
  IMPDH gene regulation 75–84

H411E rat hepatoma cells, bilirubin UGT1*1 gene expression 87–94
H630 cell line
  FU resistance 171–3
  thymidylate synthase expression 145–6
half-lives ($t_{1/2}$)
  bone marrow enzymes 47–8
  phospholipase C 48, 50–1
heart, phosphatidylinositol 4-phosphate 5-kinase IIα 127
hemagglutinin
  cleavage sites for virus activation 328
  tryptase Clara cleavage 331
hemodialysis, amyloidosis 307–22
Hep G2 cells, bilirubin UGT1*1 gene expression 93–4
hepatectomy, retinoblastoma gene product 291–2
hepatic endoplasmic reticulum, bilirubin UGT gene regulation 85–95
hepatic *mdr2* P-glycoprotein, bile salts influence on expression 351–61
hepatic transcription factor 217
hepatobiliary excretion, MRP 17–29
hepatocarcinogenesis, P-glycoprotein expression 353
hepatocytes
  canalicular membrane: MRP 18
  in vitro evidence lipogenic enzyme expression 203–4
  mdr2 P-glycoprotein expression 351–61
  membrane transport protein 24–5
  retinoblastoma gene transcription in rat 284–9
hepatomas
  AH7974 rat cells: leupeptin 268–9
  growth rates 36
  percent increase in enzymatic activity 40
HePC *see* hexadecylphosphocholine
HePNS *see* hexadecylphosphonoserine
HePS *see* hexadecylphosphoserine
hereditary defects, MRP 18
heterotrimeric G proteins, phosphatidylinositol 4-phosphate 5-kinase regulation 130–2
hexadecylphosphocholine (HePC)
  antitumour activity 386, 400
  bombesin-induced inhibition of calcium release 399
  growth-inhibitory effect 392–3
  phospholipase D inhibition 397–8
  PI-specific PLC/PKC inhibition 387
  PKC inhibition 387
  structure 388
hexadecylphosphonoserine (HePNS)
  growth inhibitory effect 393
  phospholipase D inhibition 397–8
  PKC inhibition 387
  structure 388
hexadecylphosphoserine (HePS)
  growth-inhibitory effect 392–3
  phospholipase D inhibition 397–8
  PKC inhibition 387, 396
  structure 388
hexokinase
  diabetic rats 205
  glucose phosporylation 199, 213
  L-pyruvate kinase (L-PK) 208, 213
hexosamine pathway, lipogenic enzyme expression 210
hexosaminidase, baicalein inhibition 275
hexose-6-phosphate, lipogenic enzyme expression 212, 218–19
high performance liquid chromatography (HPLC)
  folylpolyglutamates separation 369, 375
  V3 loop peptides cleavage products analysis 340
[^{3}H]inositol phosphates: lithium effects, phospholipase C (PLC) 250
HIV-1 *see* human immunodeficiency virus-1
HL60 cells, MRP function 19
HMEC cells 36, 43
HNF4 217

HPLC *see* high performance liquid chromatography
HT1080 cells, collagenase activity 270–1
HuH-7 cells, retinoblastoma gene transcription 286, 289–90, 292–7
human antileukoprotease, tryptase Clara inhibition 333
human bilirubin UDP-glucuronosyltransferase (bilirubin UGT, EC. 2.3.1.17), gene regulation 85–95
human breast cancer
GFAT transcription 210
MDA-MB-435 cells
neoplastic expression 45
signal transduction 36, 43
human breast HMEC cells, signal transduction enzymes 43
human carcinoma cells, increased signal transduction 41–3
human CD4+ cells, HIV-1 infection 336
human colon cancer cells, TS ribonucleoprotein 155, 157
human immunodeficiency virus-1 (HIV-1)
gp120 membrane fusion 336
III_B V3 loop peptide 337–42
proteolytic activation 325–44
recombinant HIV-1 SF2 gp120 proteolytic cleavage 339
human KB epidermoid carcinoma cells, murine Lometrexol antifolate activity 368, 371
human leukocyte elastase (HLE), mucous protease inhibitor activity 333
human liver, bilirubin UGT1*1 gene expression 85–95
human metallothionein IIa promoter, rTSβ expression 175–6
human mucous protease inhibitor (MPI), tryptase Clara inhibition 333–6
human neuroblastoma, phosphoinositide signalling: lithium inhibition 245–61
human neuroblastoma cells, lithium effects on phosphoinositide signalling 245–60
human neutrophil elastase, mucous protease inhibitor activity 334
human ovarian carcinoma cells, signal transduction enzymes 43
hydrophobicity, biliary phospholipid secretion 357
7α-hydroxylase, bile salts role in gene regulation 360–1
hyperbilirubinaemia
bilirubin UGT1 mutations/defects 86
bilirubin UGT1 regulation 92, 93
IGF-1, growth factors 105–6, 109–11
imipramine, NMDA receptor regulation 241
immunoblot analysis *see* Western immunoblot analysis
immunofluorescence, retinoblastoma gene product 294, 296
immunofluorescent cell counting
influenza virus A/Aichi/2/268 (H3N2) in MDCK cells 329–30
pneumotropic animal virus activation 325–44
immunoglobulins
anti-tryptase Clara effects in rat lung 332
enhancer binding proteins 216
immunoprecipitation
recombinant thymidylate synthase 167, 175
retinoblastoma gene transcription 286, 292
RT:PCR method, thymidylate synthase RNP complexes 154–5, 156
thymidylate synthase 147, 154–5
immunoreactive proteins, PIP5Ks purification/characterization 119–20
influenza A virus
A/Aichi/2/268 (H3N2), proteolytic activation 328–30
proteolytic activation 325–36
inosine monophosphate dehydrogenase (IMPDH, EC 1.1.1.205), type I/II genes expression 75–84
inositides, nuclear signalling 101–114
inositol 1,4,5-trisphosphate
extracellular calcium ions effects 255–6
lithium-stimulated accumulation 229–44
phosphoinositide signalling 230, 245–64
inositol 1,4,5-trisphosphate (IP_3)
cycloheximide 46–7
PI kinase 48–51
rat
bone marrow 46–7
fasting and refeeding 35, 46, 48–50
hepatomas 35, 37–41, 45–6
regulation 33, 35, 43–5, 46
stability 43–5
tiazofurin 46, 48
inositol 1:2 cyclic(4,5) trisphosphate, lithium effects on phosphoinositide signalling in human neuroblastoma cells 251
inositol lipid cycle, nuclear signalling 101–114
inositol monophosphatase (EC 3.1.3.25), phosphoinositide signalling in human neuroblastoma 245

inositol phosphates
N1H3T3 fibroblasts 391
second messengers, biphasic effect of lithium ions 245–64
inositol-1,4,5-trisphosphate (IP_3), phospholipid analogues inhibition of formation 394–6, 400
insulin
activating effect 184
lipogenic enzyme gene expression 199, 202–4, 208, 221
mannoheptulose effects on secretion 208
PDH regulation 184, 190–4, 194–6, 196
signalling pathways 191–4
insulin-like growth factor-1 (IGF-1), PLC β_1 regulation 101, 105, 106, 109–11, 119–111
interferon-τ (IFN-t), thymidylate synthase induction 148
Invitrogen (pMEP4), transfection of rTSα 168
IP_3 *see* inositol 1,4,5-trisphosphate; inositol 1,4,5-trisphosphate
IRE *see* iron-responsive element
IRF *see* iron-responsive factor
Irinotecan (CPT-11), anticancer activity 143
iron-responsive element (IRE), ferritin translational regulation 154
iron-responsive factor (IRF), ferritin translational regulation 154
isoelectric focussing *see* sodium dodecyl sulphate-polyacrylamide gel electrophoresis
isoenzymes
bilirubin UGT gene regulation 85–95
IMPDH type I/II 75–84
PI-specific PLC 400
protein kinase C family 105, 386–7
isoforms
folate receptors 365
phosphatidylinositol 4-phosphate 5-kinase family 105, 117–23
phosphatidylinositol 4-phosphate 5-kinases regulation 134
reduced folate carrier 365

jaundice, bilirubin UGT gene regulation 87
Jurkat T cells, IMPDH gene expression 77, 88

K562 cells
differentiation by tiazofurin 104
immunoprecipitation 167, 174–5
MTX-resistant cells 170–1
K-ras-N1H3T3 cells, mannostatin A inhibition 276
K-ras-NIH3T3 cells
conophylline inhibition 279
oxanosine inhibition 278
kainate channels, IP_3 formation in mouse/rat cerebral cortex 240
KB cells (ATCC CCL 17), recombinant thymidylate synthase transfection 168
ketamine, effects of receptor antagonists on lithium-stimulated accumulation of inositol 1,4,5-trisphosphate 231
ketanserin, inositol 1,4,5-trisphosphate lithium-stimulated accumulation in monkey brain 231–2
kidney
murine Lometrexol antifolate activity 368–75
phosphatidylinositol 4-phosphate 5-kinase IIα 127
kinases
activity, PDH regulation 183–4, 190
phosphatidylinositol 4-phosphate 5-kinase family 115–40
knockout mice, *mdr1a/mdr2* gene, biliary lipid secretion effects 352–7
Kunitz type II protease inhibitor, V3 loop sequences 336

L-pyruvate kinase (L-PK)
azaserine 210
expression
glucose effect 210, 214–18, 220–1
glucose metabolism 207–9
lipogenic enzyme expression 208–9
transcription
glycolytic metabolites 213
hexose-6-phosphate 213
starved rats 213
Lactobacillus casei enzyme 152
lactose operon, *Escherichia coli* 219
lamellipodia, EGF 132
leukotrienes
export pump, MRP 18, 26
LTD_4
ATP-dependent LTC_4 transport 22
MK 571 18
PIP5K stimulation 133
receptor antagonists, MRP 18
leukovorin, chemotherapy with 5-FU 143–5
leupeptin, antimetastatic activity *in vitro* 268–71
Lewis lung carcinoma
epi-cyclophellitol inhibition 275

murine Lometrexol antifolate activity 368, 371
LFD *see* low folate diet
lipid secretion, biliary 351–61
lipogenesis
enzyme expression
hexose-6-phosphate 219
isolated hepatocytes 203–4
metabolites 209–11
regulation by glucose in liver and adipose tissue 199–226
insulin 195
pathway 200
PDH 190
rate
FAS activity 202–3
glucose 202–3
mRNA concentration 202–3
lipophilic inhibitors
PC-PLC 65–8
PI-PLC 62–4
lithium
ACh dose response curves 251–3
biphasic effect on the level of the inositol phosphate second messengers 245–64
glutamate release via cerebral NMDA receptor activation 229–44
inositol 1,4,5-trisphosphate accumulation 229–44
toxicity 242
liver
apoptosis, gene products expression 292–7
human bilirubin UGT gene regulation 85–95
lipogenic enzyme expression regulation by glucose in liver and adipose tissue 199–226
mdr2 P-glycoprotein expression 351–61
MRP function 23–4
murine Lometrexol anti-folate activity 368–75
phosphatidylinositol-4-phosphate 5-kinases 115, 127
rat lysosomal enzymes, hemodialysis-associated amyloidosis 307–17
regeneration, retinoblastoma gene product 291–2
Lometrexol
folate status 375–8
toxicity/efficacy 365–81
low folate diet (LFD), Lometrexol antitumour activity 367–78
LT *see* leukotriene
LTC_4 *see* leukotriene C_4
luciferase gene, bilirubin UGT1 gene expression 88–95
lung
murine melanoma metastases 273–5
phosphatidylinositol 4-phosphate 5-kinase IIα 127
viral infection, cellular proteases 325–44
LY231514 cells 367, 367
LY309887 cells 367
2-lysophosphatidylcholine, antitumour activity 386
lysosomal enzymes
hemodialysis patients' serum levels 319–22
hemodialysis-associated amyloidosis 307–14
serum activity 318–19
lysosomes
purification 308–9
serum albumin proteolysis 308–10, 314, 318–19, 321

M5 ovarian carcinoma, murine Lometrexol antifolate activity 368, 371
Madin-Darby canine kidney cells (MDCK), influenza virus A/Aichi/2/268 (H3N2) 330, 334
magnesium ions, tryptase Clara activation 328
malic enzyme
glucose effect 220
lipogenesis activity 202
malignant transformation, phospholipid analogues inhibition of mitogenic signalling induction 385–402
mammalian cells, gp120 oligosaccharide structure 338
mammalian phosphatidylinositol 4-phosphate 5-kinase, regulation/function 128–35
mammalian virus activation, proteolytic 325–44
mammary carcinoma, murine Lometrexol antifolate activity 367–78
mandelate racemase (EC 5.1.2.2) 169
manic depression
lithium action mechanism 229–44
lithium effects on phosphoinositide signalling in human neuroblastoma cells 245–60
mannoheptulose
ACC expression 208
glucokinase inhibitor 209
insulin secretion 208
mannose 212
mannose-6-phosphate 212, 214
glucose-6-phosphate 212, 214

α-mannosidase, baicalein inhibition 275
mannostatin A
  antimetastatic activity 276
  structure 272
mast cell chymase, mucous protease inhibitor activity 334
matrix metalloproteases (MMPs)
  leupeptin analogues inhibition 269–71
MDA-MB-435 human breast carcinoma cells 43
  lag phase 45, 53
  log phase 45, 53
  neoplastic expression 45
  plateau phase 45, 53
  signal transduction 36
mdr1 gene expression, P-glycoproteins 352–3, 354, 355
mdr2 gene expression, bile salts influence 357–60
mdr3 gene expression, P-glycoproteins 352–3
mechanism based inhibitors, phospholipase C enzymes 57–71
melanoma
  murine
    antimetastatic glycosidase inhibitors 272–5
    Lometrexol antifolate activity 368, 370–2
membrane fusion, HIV-1 envelope glycoprotein gp120 336
membranes *see* cell membranes
messenger RNA (mRNA)
  lipogenesis activity 202–3
  mdr2 expression 357–61
  reverse transcription PCR and sequencing 19–20
  thymidylate synthase 145, 159, 165, 173
  transcription *in vitro* 146
metabotropic receptors, lithium-stimulated glutamate release/IP_3 accumulation 229–44
metal chelation, rTSα/rTSβ carboxy regions homology 168–70, 175–6
metallothionein IIa promoter, rTSβ expression 175–6
metastases
  folic acid 375–6
  in vitro inhibition 267–81
methionine synthase (MS), folate utilization 366
methotrexate (MTX)
  dihydrofolate reductase modulation 153
  K562 B1A resistant cells, recombinant thymidylate synthase overexpression 170–1
  K562 resistant cells, recombinant thymidylate synthase overexpression 170–1
  recombinant thymidylate synthase proteins 166
mice
  C3H mammary tumour, Lometrexol activity 367–75
  cerebral cortex, lithium action mechanism 229–44
  Lometrexol antitumour activity 367–73
  low folate diet effect on folate receptor density/affinities 371
  mdr2 gene expression 352–60
  melanoma, glycosidase inhibitors 272–5
  transgenic, retinoblastoma protein expression 284
micelles, short-chain phospholipid 62
Michael adducts, RNA/protein interactions 152
β-microglobulin, hemodialysis-associated amyloidosis 307, 320, 322
microorganisms, antimetastatic agents 267–81
mitochondria
  Ca^{2+} 186, 188–90
  matrix: PDH system 184
  PDH regulation 183–98
mitogenic signal transduction
  PC-specific phospholipase C 387
  phospholipid analogues inhibition 385–402
MK 571 22
(±)MK-801, effects of receptor antagonists on lithium-stimulated accumulation of $Ins(1,4,5)P_3$ 231
MMPs *see* matrix metalloproteases
MOAT *see* multispecific organic anion transporter
monkeys
  cerebral cortex, lithium action mechanism 229–44
  kidney cell fibroblasts (COS-7), bilirubin UGT1*1 gene expression 89–90, 93, 95
monoclonal antibodies
  cell cycle-related gene expression assay 296
  neoplastic cell-surface carbohydrate structures 272
  V3 loops antibody 338–9
morphology, apoptosis evaluation 285, 288–9
mouse *see* mice
mRNA *see* messenger RNA
MRP *see* multidrug resistance protein
MSS4 124–8

MTX *see* methotrexate
mucous protease inhibitor (MPI), tryptase
  Clara inhibition 333
multidrug resistance (MDR)
  see also mdr genes
  P-glycoproteins expression 351–61
multidrug resistance protein (MRP)
  drug conjugate transport 17–29
  gene-encoded conjugate export pump
    altered localization 26
    ATP-dependent transport 17–18, 20–2, 26
    hereditary defect in canalicular membrane 24–6
    inhibitors 22
    liver 18, 23–4
    localization in liver 24, 25
    overexpression 22
    substrate specificity 20–2
  hepatobiliary excretion 17–29
multispecific organic anion transporter (MOAT) 18, 26
muricholate, biliary secretion 357, 361
murine *see* mice
muscarinic receptors
  human neuroblastoma cells
    phosphoinositide signalling 246
  lithium effects on phosphoinositide signalling in human neuroblastoma cells 253–5
MX-1 mammary carcinoma, murine
  Lometrexol antifolate activity 368, 371, 373
MyD118 298
myeloma, murine Lometrexol antifolate activity 368, 371
myo-inositol 1,2-cyclic monophosphonates 60

N1H3T3 fibroblasts, phospholipids effects on mitogenic signalling 389–94
N-acetyl cysteine, MRP substrate 26
N-methyl [D]-aspartate (NMDA) receptors, lithium-stimulated activation 229–44
NAD^+-isocitrate dehydrogenase (EC 1.1.1.41)
  calcium ions 185–6
  PDH phosphatase 195
NADH:NAD^+ ratios, kinase activity 183–4
NADH, PDH 183, 186
NADPH, lipogenesis pathway 200
Narke japonica, PIP5K activity 130
neonatal jaundice, bilirubin UGT1*1 gene expression 87
neuroblastoma, phosphoinositide signalling: lithium inhibition 245–61
neurotransmitters
  antagonists, inositol-1,4,5-trisphosphate lithium-stimulated accumulation in monkey brain 231–3
  glutamate release in monkey/mouse brain 229–43
  phosphatidylinositol 4-phosphate 5-kinase family 115–35
  receptors, phospholipase C activation 245
Newcastle disease virus, proteolytic activation 325
NIH3T3 cells, metastasis inhibition 277–9
NMR *see* nuclear magnetic resonance studies
NOEs
  intramolecular 66–8
  NMR energy minimized models 63
non-ciliated secretory airway epithelial cells 328, 333
non-planar phenols, bilirubin UGT substrate specificity 86
norephinephrine, anti-manic effect 241
normal ovaries, increased signal transduction 41–3
Northern blotting, *mdr2* gene mRNA 357–60
nuclear magnetic resonance (NMR) studies
  NOEs: energy minimized models 63
  phospholipase C enzymes 59
nuclear phosphoinositides
  isoforms regulation 134
  phosphoinositide cycle 133
  pool cycle 116
nuclear signalling, inositol lipid cycle 101–114
nuclei, apoptotic morphology 285, 288–9

3-O-methyl glucose
  ACC expression 205, 208
  FAS expression 205
okadaic acid
  glucose signal transmission 219
  retinoblastoma gene product changes during apoptosis 286, 289–92
S-oligonucleotides, retinoblastoma gene transfection 287
oligosaccharides
  recombinant gp120 in baculovirus-infected insect cells 338
  tumor cell surface 271–5
oncogenes
  function inhibitors antimetastatic activity 276–80

growth factors, phospholid analogues inhibition 385–402
Oroxylum indicum, baicalein 275
orthomyxoviruses, proteolytic activation 325–36
ovarian carcinomas
increased signal transduction 35, 41–3
murine Lometrexol antifolate activity 368, 371–2
OVCAR-5 cells, signal transduction 36, 41–3
overexpression
P-glycoproteins 352
retinoblastoma gene product 297–8
oxanosine, Ras function inhibition 277, 278
oxoglutarate dehydrogenase (EC 1.2.4.2) 185, 194, 195

p19 LUC, bilirubin UGT1 gene functional analysis 88–90
p53
cell cycle-related expression 292–3, 296–7
gene product, retinoblastoma gene transcription 283
mRNA, thymidylate synthase protein interactions 157–8
retinoblastoma gene product inhibition of apoptosis 298–300
tumor suppressor gene, thymidylate synthase mRNA interaction 155–7
p70 S6kinase activation, insulin 191–3, 194
S31sP NMR spectroscopy
PI-PLC assays 60–2
PI-PLC inhibitors 64
P-glycoproteins (Pgp), bile salts influence on expression 351–61
PANC-1 pancreatic carcinoma, murine Lometrexol antifolate activity 368, 371–2
pancreas
carcinoma, murine Lometrexol antifolate activity 368, 371–2
phosphatidylinositol 4-phosphate 5-kinase IIa 127
trypsin, pneumotropic animal virus activation 335
paramyxoviruses, proteolytic activation 325–36
partial hepatectomy, retinoblastoma gene product 291–2
PC-PLC *see* phosphatidylcholine-specific phospholipase C
PC-PLD *see* phosphatidylcholine-specific phospholipase D
PCR amplification, MRP expression 23–4, 26
PDC *see* pyruvate dehydrogenase complex
PDH *see* pyruvate dehydrogenase
pentose-phosphate cycle
FAS gene 213
lipogenic enzyme expression 210
peripheral blood T lymphocytes, IMPDH gene expression 77–82
Pgp *see* P-glycoproteins
pH, cytoplasmic 390
pharmacokinetics, Lometrexol distribution with low folate diet 373–5
Phellinus mushroom, cyclophellitol 272
phenobarbital
'BARBIE BOX' 91, 94–5
bilirubin UGT gene regulation 88, 89, 91, 94–5
phenols, bilirubin UGT substrate specificity 86
phentolamine, inositol-1,4,5-trisphosphate lithium-stimulated accumulation in monkey brain 231–2
phenytoin, bilirubin UGT1*1 gene expression 89, 93
phosphatidylcholine-specific phospholipase C (PC-PLC, EC 3.1.4.3), diacyl-sn-(3-N-benzylaminoglycero) phosphoramidocholine 69
phorbol 12-myristate 13-acetate (PMA), IMPDH gene expression 77
phosphatidylcholine
pneumotropic animal virus activation 335
translocation 353–4
phosphatidylcholine-specific phospholipase C (PC-PLC, EC 3.1.4.3)
activities 57–8, 59
characteristics 57–71
1,2-dihexanoyl-sn-(3-N-benzylaminoglycero) phosphoramidocholine 60, 66–7
inhibitors 65–9, 65–70
isoenzymes 400
lipophilic inhibitors 65–8
mitogenic signalling 387
phospholipid analogues inhibition 387, 393, 395–7
vanadate 68–9
water soluble inhibitors 60, 65
phosphatidylcholine-specific phospholipase D (PC-PLD), mitogenic signalling 400–1
1-phosphatidylinositol 4-kinase (PI kinase, EC 2.7.1.67) 34–5
cycloheximide 46–7
fasting and refeeding 48–50

HMEC cells 43
human carcinoma cells 42–3
MDA-MB-435 cells 43, 45
rat hepatomas 37–41
tiazofurin 48
1-phosphatidylinositol 4-phosphate 5-kinase (PIP kinase, EC 2.7.1.68) 34
cycloheximide 46–7
family 115–40
fasting and refeeding 48–50
human carcinoma cells 41–3
IP_3 concentration 48
isoforms regulation 134
MDA-MB-435 cells 43
rat hepatomas 37–41
tiazofurin 48
phosphatidylinositol
lithium effects on phosphoinositide signalling 246
lithium-stimulated breakdown in rat cerebral cortex 241
mitogenic signalling 387
phosphatidylinositol transfer protein (PITP)
inositides and nuclear signalling 110, 116
phosphoinositide kinases 129, 132
phosphatidylinositol-4,5-bisphosphate
cellular pools 116
lithium effects on phosphoinositide signalling 246
phosphoinositide cycle 115
vesicular trafficking 129
phosphatidylinositol-specific phospholipase C (PI-PLC, EC 3.1.4.11)
^{31}P NMR assays 60–2
bacterial reaction scheme 61
characteristics 57–71
inhibitors 60, 62–5, 69
lipophilic inhibitors 62–4
phosphatidylinositol-mediated signalling pathways 69
phospholipid analogues inhibition 387, 393, 395–7, 400
reaction scheme 61
short-chain phospholipid micelles 62
water soluble inhibitors 64–5
phosphatidylserine, pneumotropic animal virus activation 335
phosphoenolpyruvate carboxykinase (EC 4.1.1.32)
L-PK transcription 213
lipogenic enzyme expression 203
6-phosphofructokinase (PFK, EC 2.7.1.11), glucose-6-phosphate 213
phosphoglucoisomerase, glucose-6-phosphate 213
phosphoglycoproteins *see* P-glycoproteins
phosphoinositide cycle
diagram 116
kinases 132
nuclear phosphoinositides 133
phosphatidylinositol-4-phosphate 5-kinase family 115–35
phosphoinositide signalling, lithium inhibition 245–64
phosphoinositides cycle, lithium action 229–44
phospholipase C (PLC, EC 3.1.4.11)
[^{3}H]inositol phosphates: lithium effects 250
autonomous nuclear signalling 101–114
cycloheximide 46–7, 51
HMEC cells 43
inhibitors 57–71
lithium action 242–3
long half-life 48, 50–1
nonspecific 57–8, 59
nutritional control 51
properties 51–2
rat hepatomas 37–41
role in neoplasia 50
role in regulatory events 50
signal transduction regulation 33, 34, 38–54
specific 69
starvation 49–50
phospholipase C (PLC, EC 3.1.4.3.), mitogenic stimulation 387
phospholipase C-τ (PLC-τ), activation 400
phospholipase D (PLD, EC 3.1.4.4)
activity determination 391–2
phospholipid analogues inhibition 397–8, 401
PtdIns [4,5]P_2 stimulation 129
phospholipid analogues
IP_3 formation inhibition 394
membrane damage 398–9, 401
mitogenic signal transduction inhibition 385–402
PI-specific PLC inhibition 393–5
PKC activity 394
structures 388
toxicity 398
phospholipid secretion, bile salts influence 351–60
phosphoramidocholine, synthesis 60
phosphorimaging, mRNAs 173
phosphorylation, retinoblastoma gene product 291, 296
PI-PLC *see* phosphatidylinositol-specific phospholipase C
PIP_2, PLC 51, 52
PIP kinase *see* 1-phosphatidylinositol 4-phosphate 5-kinase

PKC *see* protein kinase C
placenta, phosphatidylinositol 4-phosphate 5-kinase IIa 127
plant-derived antimetastatic agents 267–81
plasma albumin, hemodialysis-associated amyloidosis 307–322
plasma membrane
  phosphatidylinositol [4,5]bisphosphate 116
  phosphatidylinositol-4-phosphate 5-kinases 115
plasmin
  leupeptin inhibition 269–71
  pneumotropic animal virus activation 335
plasminogen, leupeptin analogue inhibition 270–1
pMEP4 (Invitrogen), transfection of recombinant thymidylate synthase 168
pneumotropic virus infection, tryptase Clara 325–44
polyacrylamide gel electrophoresis (PAGE), serum albumin in hemodialysis-associated amyloidosis 307–17
polyclonal antibodies
  PIP5Ks purification/characterization 117
  recombinant HIV-1 SF2 gp120 proteolytic cleavage 339
polyphosphoinositide pools
  isoforms regulation 134
  phosphoinositide cycle 115–18, 134
post-translational cleavage
  mammalian enveloped viruses 337–47
  viral envelope glycoproteins 328–44
potassium ions, insulin on PDH 194
pRb *see* retinoblastoma protein
priming of exocytosis (PEP) proteins, phosphatidylinositol 4-phosphate 5-kinase activity 129
programmed cell death *see* apoptosis
promoter regions
  bilirubin UGT gene regulation 88, 90, 93, 94
  IMPDH gene expression 77–82
  SV40 88
proteases
  animal virus activation 325–44
  hemodialysis-associated amyloidosis 307–17
  inhibitors, antimetastatic activity 268–71
protein
  expression, thymidylate synthase 146, 148, 165, 171–3
  lytic cleavage
    hemagglutinin 328
    HIV-1 gp120 proteolysis 327–8, 338
    HIV-1 III_B V3 loop peptide 327–8, 342, 343
    tryptase Clara 331, 343
    V3 loop peptides 327–8
  lytic enzymes
    albumin modification during hemodialysis 317–18
    amyloid deposition in hemodialysis patients 307–22
    tryptase Clara 325–44
  purification, phosphatidylinositol 4-phosphate 5-kinase II 123
  sequencing
    phosphatidylinositol 4-phosphate 5-kinase II 123
    rTSα/rTSβ carboxy regions 168–70
protein kinase C (PKC)
  activation 57–8
  hexadecylphosphocholine growth-inhibitory effect 392–3
  7α-hydroxylase gene transcription 361
  lithium efffects on inositol-1,4,5-trisphosphate levels in human neuroblastoma cells 257–9
  nuclear inositol lipid cycle 105–9
  phospholipid analogues effects 386–7, 394, 395–8, 400–1
  $PLC_{\beta 1}$ isoform 102
  preparation 389–90
Pseudomonas putida, proteins homology 169
PtdIns $[4,5]P_2$ *see* phosphatidylinositol[4,5]bisphosphate
pulmonary surfactants, tryptase Clara inhibition 333, 335–6
purine biosynthesis
  folate cofactors 365
  IMPDH gene expression 75–84
  signal transduction regulation 33, 35, 37–54
pyrimidine
  signal transduction regulation 33, 35
  trifluorothymidine analogue 166, 170, 176
pyroglutamyl (Pyr)-Leu-Arg-CHO, leupeptin analogue inhibition 269–71
pyruvate decarboxylase (E1) units 183
pyruvate dehydrogenase (PDH, EC 1.2.4.1)
  hormonal regulation 183–98
  PDC complex
    activation 187, 190
    glucose effect 220
  regulation
    fat cells permeabilized by electroporation 194–5
    insulin 190–4, 196

mitochondria 183–98
reversible phosphorylation 183–4
pyruvate dehydrogenase phosphatase 195
pyruvate kinase, lipogenic enzyme expression 208
L-pyruvate kinase (L-PK)
azaserine 210
expression
glucose effect 210, 214–18, 220–1
glucose metabolism 207–9
lipogenic enzyme expression 208–9
transcription
glycolytic metabolites 213
hexose-6-phosphate 213
starved rats 213

QUANTA modelling, phospholipase C enzymes 63
quercetin, IP_3 concentration 46

Rac proteins, phosphatidylinositol 4-phosphate 5-kinase regulation 131–3
radioactive labelling, [^{3}H]inositol phosphates: lithium effects 250
radiolabelling ^{14}C-Lometrexol pharmacokinetics 373–5
rapamycin, PDH regulation 191–2, 193
Ras function inhibitors
conophylline 279
oxanosine 278
rate-limiting enzyme concept 39
rats
bilirubin UGT gene regulation 89
bone marrow, IP_3 concentration 46–7
liver
AH7974 cells 268–9
amino acid sequence alignments 23
hemodialysis-associated amyloidosis 307–17
P-glycoprotein expression 353–61
retinoblastoma gene 284–9, 291–2
signal transduction enzymes 35–6, 37–41, 45–6
lung, tryptase Clara 325–44
mast cell tryptase, pneumotropic animal virus activation 335
phosphatidylinositol 4-phosphate 5-kinase regulation 131
RB see retinoblastoma gene
receptor antagonists, inositol-1,4,5-trisphosphate lithium-stimulated accumulation in monkey brain 231
recombinant HIV-1 SF2 gp120, protease TL2 cleavage 327–8, 337–9
recombinant mucous protease inhibitor (rMPI), activity in *E. coli* 333
recombinant soluble CD_4 ($rsCD_4$), HIV-1 gp120 cleavage 327, 338
recombinant thymidylate synthase α (rTSα)
transfection 168
trifluorothymidine alteration 175–6
recombinant thymidylate synthase β (rTSβ), transfection 168
recombinant thymidylate synthase (rTS)
antiserum 172
gene expression, thymidylate synthase inhibitors 165–80
homologs 170
immunoprecipitation 167, 174–5
natural occurrence 165–6
overexpression
FU resistant cells 171–2, 176
MTX-resistant K562 B1A cells 170–1, 176
phosphorimaging 173
phylogenetic conservation 168–70
resistance to TS inhibitors 170–2
TS physical association 172–5
TSmRNA protein binding 146–7
reduced folate carrier 365
regeneration, liver 291–2
renal failure, hemodialysis-associated amyloidosis 307–17
reporter gene constructs
bilirubin UGT1*1 drug induction 92, 93
bilirubin UGT1*1-2kb activity 90
IMPDH gene expression 79
luciferase 88–95
respiratory epithelium, tryptase Clara-mediated virus activation 325–44
retinoblastoma gene (*RB*)
apoptosis 283–303
apoptosis modulation 283–303
cell cycle-related expression 292–7
E2F-1 activity in apoptosis 300
retinoic acid, bilirubin UGT1*1 gene expression 92
reverse transcriptase-polymerase chain reaction (RT-PCR) analysis, thymidylate synthase 147–8, 154–6
reversible phosphorylation, PDH 183–4
Rho proteins, phosphatidylinositol 4-phosphate 5-kinase regulation 130–3, 131–3
ribonucleoprotein (RNP) complexes, thymidylate synthase 147, 154–5
rMPI *see* recombinant mucous protease inhibitor
RNA binding protein, thymidylate synthase 157–9
RNP *see* ribonucleoprotein (RNP) complexes
$rsCD_4$ *see* recombinant soluble CD_4

RT-PCR *see* reverse transcriptase-polymerase chain reaction
rTS *see* recombinant thymidylate synthase
ruthenium red, Ca^{2+} inhibition 187

S14 *see* Spot 14 gene
Saccharomyces cerevisiae, phosphatidylinositol 4-phosphate 5-kinase II 123–4, 133
Saos-2 cells, retinoblastoma gene product inhibition of apoptosis 298–9
SDS-PAGE *see* sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)
second messengers
  inositol lipid cycle 101–114
  phosphoinositide signalling in human neuroblastoma 245–61
secretory leukoprotease inhibitor (MPI), tryptase Clara inhibition 333
secretion
  bile salts influence on *mdr2* P-glycoprotein expression 351–61
  phosphatidylinositol 4-phosphate 5-kinase 128–30
Sendai virus, proteolytic activation 325–36
sequencing
  phosphatidylinositol 4-phosphate 5-kinase II 123–6
  rTSα/rTSβ carboxy regions 168–70
  tryptase Clara cleavage products 331
  V3 loop peptide cleavage 340–2
serine hydroxymethyl transferase (SHMT), folate utilization 366
serine/threonine kinases, phospholipid analogues inhibition 386–7
serotonin, anti-manic effect 241
serum albumin
  AGE modified 322
  Alb I/Alb II
    proteolysis products 307, 317–19, 321–2
    ratio in longterm hemodialysis 307–22
  hemodialysis-associated amyloidosis 307–17
SH2/3 domains, PI-specific PLC inhibition 400
SH-SY5Y neuroblastoma cells, lithium effects on phosphoinositide signalling 246–60
signal transduction
  cancer cells 34
  enzyme comparison 50
  enzyme steady-state activities 52
  fat cells permeabilized by electroporation 194–5
  guanine nucleotides 75
  increased 41–3
  inositol lipid cycle 101–112
  insulin 191–4
  malignancies 34, 37–41, 267–81
  metastasis inhibition 267–81
  multi-enzyme sequence 34–5
  PDH regulation 184
  phospholipid analogues inhibition of mitogenic signalling induction 385–402
  regulation of 33–55
skeletal muscle, phosphatidylinositol 4-phosphate 5-kinase IIα 127
small G proteins, phosphatidylinositol 4-phosphate 5-kinase regulation 130–2
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)
  influenza virus A/Aichi/2/268 (H3N2) glycoproteins 329–30
  serum albumin in hemodialysis-associated amyloidosis 307–17, 321
  tryptase Clara 329, 331
  viral envelope polypeptides analysis 326
sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), serum albumin from hemodialysis patients 307–17
sodium/hydrogen ion antiporter, activation 396, 400
spermidine
  insulin-like effect 196
  PDH activation 194–5
Spot 14 gene, glucose response element 215–18
starvation
  IP_3 35, 46, 48–50
  PI kinase 48–50
  PIP kinase 48–50
  rats
    fructose 213
    glucose 213
    hepatocytes, L-pyruvate kinase (L-PK) gene 208
  signal transduction 35, 46, 48–50
staurosporine
  [^{3}H]inositol phosphates: HPLC analysis 248
  lithium efffects on inositol-1,4,5-trisphosphate levels in human neuroblastoma cells 257–61
steady-state activities
  DNA-synthesizing enzymes 39
  signal transduction enzymes 52
steroids, bilirubin UGT substrate specificity 86
sterol-27-hydroxylase, bile salts role in gene regulation 360–1

Streptomyces, leupeptin protease inhibitors 268–71
Streptoverticillum verticillus, mannostatin A 276
structure based inhibitors, phospholipase C enzymes 57–71
suckling rats
  in vitro evidence lipogenic enzyme expression 201–4
    adipose tissue 202–3
    isolated hepatocytes 203–4, 205
surfactants, pulmonary, tryptase Clara inhibition 333, 335–6
Swainsonine, metastatis inhibition 276
Swiss 3T3 cells, PLC β_1 regulation 105–7, 109–111
synthetic substrates, tryptase Clara 331

T lymphocytes, IMPDH gene expression 77, 79, 81–2
TATA box sequence, bilirubin UGT1*1 90, 92, 94
taurocholate, biliary P-lipid secretion 356–7, 360
taurodeoxycholate, biliary P-lipid secretion 357
tauroursodeoxycholate, biliary P-lipid secretion 360
terminal transferase-mediated dUTP-digoxigenin nick end labelling (TUNEL) assays
  retinoblastoma gene product overexpression 297–8
  retinoblastoma gene transfection 288
thrombin
  cytosolic free calcium 395, 401
  HIV-1 gp120 cleavage 338
  IP_3 formation 394–6
  leupeptin analogue inhibition 269–71
thymidine kinase, regulated expression 153
thymidylate synthase (TS, EC 2.1.1.45)
  c-myc mRNA 155, 157
  cellular regulation 143–63
  DNA biosynthesis 143–59
  expression of 145
  folate utilization 366
  immunoprecipitation 174, 175, 176
  inhibitors
    BW1843489 171
    ICI D1694 171
    rTS gene expression 165–80
    rTS resistance 170–2
  mRNA 145–59, 165, 173
  mRNA translation 148–50
  overexpression, FU resistant cells 171–2
  p53 mRNA 157–8
  physical association 172–5
  purification 146
  recombinant 165–80
  ribonucleoprotein complexes 154–5
  RNA binding protein function 157–9
  RNAs
    5-fluorouracil 165
    phosphorimaging 173
  rTS gene expression 165–80
  translation *in vitro* 147, 149, 153
  translational autoregulation model 151
tiazofurin
  IP_3 concentration 46, 48
  PI kinase 48
  PIP kinase 48
  PLC β_1 regulation 102–4
  rat bone marrow 48
TMQ *see* trimetrexate
toluene, mitochondria 185
tolulene, permeabilization 191
Tomudex (ZD1694) 143, 144
toxicity
  lithium 242
  Lometrexol 367, 369, 375–9
  phospholipid analogues PKC inhibition 398
trans elements, glucose-responsiveness of lipogenic enzyme expression 214–16
transcription
  bilirubin UGT1 gene 95
  bilirubin UGT1 transcription factor binding sites 91
  7α-hydroxylase gene 361
  IMPDH gene regulation 75–84
  retinoblastoma gene 283
transfection
  bilirubin UGT gene expression 88, 90
  IMPDH gene expression 77
  PLC β_1 into Swiss 3T3 cells 109–10
  retinoblastoma gene 284–7
  rTSα 168
transformed cells, IMPDH expression 75
transforming growth factor β-1 (TGF-β1)
  retinoblastoma gene product changes during apoptosis 289–92
  overexpression 297–8
transgenic knockout mice, *mdr1a/mdr2* gene 352–7
transgenic mice, retinoblastoma protein expression 284
translation
  autoregulation, thymidylate synthase model 151
  c-myc mRNA 155
translocation, biliary phospholipids 352–3, 354

transport
deficient mutant rats 19
hepatic canalicular membrane 351–4
mdr2 P-glycoprotein 351–61
trifluorothymidine, rTSa
transfection 175–6
trifluorothymidine (TFT), recombinant
thymidylate synthase expression 166, 170, 176
triiodothyronine, FAS mRNA 203
trimetrexate (TMQ), dihydrofolate
reductase modulation 153
TRNOE techniques
diacylphosphoramidocholine 59
PC-PLC 59, 68
Trypanosoma brucei,
IMPDH sequencing 79
tryptase Clara
endogenous inhibitors 333–6
influenza A/Aichi/2/68
activation 325–44
inhibition, anti-tryptase Clara
antibody 331–3
synthetic/protein substrates 331
tryptase TL2, HIV-1 gp120
binding/cleavage 327, 336–44
tryptic sites, HIV-1 III_B V3 loop peptide
cleavage 342
TS *see* thymidylate synthase (TS, EC 2.1.1.45)
tumours
IMPDH expression 75–6
increased signal transduction 41–3
inositides and nuclear
signalling 101–114
markers, folate receptor-a 365
metastatic activity 267–81
multidrug resistance 17, 22, 352
signal transduction 37–41
TUNEL *see* terminal transferase-mediated
dUTP-digoxigenin nick end labeling
assays
type IV collagenase, leupeptin analogue
inhibition 269–71
tyrosine kinase
erbstatin inhibition 276–8
insulin 191
tyrosine phosphorylation,
phosphatidylinositol 4-phosphate 5-kinase
activity 132–3

UDC *see* ursodeoxycholate
UDP-2-deoxyglucose, lipogenic enzyme
expression 211
UDP-glucose, lipogenic enzyme
expression 212
UDP-glucuronosyltransferase (bilirubin
UGT, EC. 2.4.1.17),
gene regulation 85–95
upstream stimulatory factor/major late
transcription factor (USF/MLTF),
lipogenic enzyme gene
expression 216–18, 221
uridine 8, nucleophilic attack 152
urokinase, leupeptin analogue
inhibition 269–71, 280
ursodeoxycholate (UDC), *mdr2*
expression 355–59
USF/MLTF *see* upstream stimulating
factor/major late transcription factor

V3 loop peptides
cleavage 327–8, 342
degradation products sequences 340–2
HIV-1 gp120 336–44
tryptase TL2 binding 336–44
valproate
glutamate release in manic
depression 230
glutamate release in mouse cerebral
cortex slices 237–42
valproic acid, glutamate release in mouse
cerebral cortex 240
vanadate
diabetic rats 205–6
PC-PLC inhibitor 68–9
vesicular trafficking, phosphatidylinositol
4-phosphate 5-kinase 128–30
vinblastine, P-glycoprotein pump 17
Vinca alkaloids, MRP 17
viruses
activation, proteolytic 325–44
envelope fusion proteins,
proteolysis 325–44
replication, anti-tryptase Clara effects in
rat lung 331–3
virus-cell fusion, HIV-1 infection 336
VP-16 *see* etoposides

water soluble PI-PLC inhibitors 64–5
Western immunoblot analysis
gp130/V3 loop peptides proteolytic
cleavage 327
MRP expression in rat liver 23–4, 26
recombinant HIV-1 SF2 gp120
proteolytic cleavage 339
retinoblastoma gene product changes
during apoptosis 291, 293
retinoblastoma gene transfection 287
thymidylate synthase 148

wortmannin
  acetyl-CoA carboxylase activity 194
  PDH regulation 192, 193, 194, 195

X5563 myeloma, murine Lometrexol
  antifolate activity 367–8, 371
xenobiotics
  human bilirubin UGT 85, 86, 87, 89, 94
  MRP conjugates 18, 22
  Pgps expression in liver 353

yeast artificial chromosome (YAC), human
  bilirubin UGT gene cloning 85

ZD1694 *see* Tomudex